BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ychou M, Boige V, Pignon J, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre J, Saint-aubert B, Genève J, Lasser P, Rougier P. Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial. JCO 2011;29:1715-21. [DOI: 10.1200/jco.2010.33.0597] [Cited by in Crossref: 1046] [Cited by in F6Publishing: 471] [Article Influence: 104.6] [Reference Citation Analysis]
Number Citing Articles
1 Fornaro L, Spallanzani A, de Vita F, D'Ugo D, Falcone A, Lorenzon L, Tirino G, Cascinu S; GAIN (GAstric Cancer Italian Network). Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN). Cancers (Basel) 2021;13:1304. [PMID: 33804024 DOI: 10.3390/cancers13061304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Bausys A, Senina V, Luksta M, Anglickiene G, Molnikaite G, Bausys B, Rybakovas A, Baltruskeviciene E, Laurinavicius A, Poskus T, Bausys R, Seinin D, Strupas K. Histologic Lymph Nodes Regression after Preoperative Chemotherapy as Prognostic Factor in Non-metastatic Advanced Gastric Adenocarcinoma. J Cancer 2021;12:1669-77. [PMID: 33613754 DOI: 10.7150/jca.49673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Harada K, Mizrak Kaya D, Baba H, Ajani JA. Recent advances in preoperative management of esophageal adenocarcinoma. F1000Res 2017;6:501. [PMID: 28491289 DOI: 10.12688/f1000research.10794.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Martin-Romano P, Solans BP, Cano D, Subtil JC, Chopitea A, Arbea L, Lozano MD, Castanon E, Baraibar I, Salas D, Hernandez-Lizoain JL, Trocóniz IF, Rodriguez J. Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling. PLoS One 2019;14:e0215970. [PMID: 31071108 DOI: 10.1371/journal.pone.0215970] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Smyth EC, Nyamundanda G, Cunningham D, Fontana E, Ragulan C, Tan IB, Lin SJ, Wotherspoon A, Nankivell M, Fassan M, Lampis A, Hahne JC, Davies AR, Lagergren J, Gossage JA, Maisey N, Green M, Zylstra JL, Allum WH, Langley RE, Tan P, Valeri N, Sadanandam A. A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial. Ann Oncol. 2018;29:2356-2362. [PMID: 30481267 DOI: 10.1093/annonc/mdy407] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
6 Hoeppner J, Plum PS, Buhr H, Gockel I, Lorenz D, Ghadimi M, Bruns C; Qualitätskommission der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie. [Surgical treatment of esophageal cancer-Indicators for quality in diagnostics and treatment]. Chirurg 2021;92:350-60. [PMID: 32876700 DOI: 10.1007/s00104-020-01267-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kano M, Hayano K, Hayashi H, Hanari N, Gunji H, Toyozumi T, Murakami K, Uesato M, Ota S, Matsubara H. Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis. Ann Surg Oncol 2019;26:1805-13. [PMID: 30977014 DOI: 10.1245/s10434-019-07299-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
8 Norton JA, Kim T, Kim J, McCarter MD, Kelly KJ, Wong J, Sicklick JK. SSAT State-of-the-Art Conference: Current Surgical Management of Gastric Tumors. J Gastrointest Surg 2018;22:32-42. [PMID: 28808875 DOI: 10.1007/s11605-017-3533-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Qian J, Qian Y, Wang J, Gu B, Pei D, He S, Zhu F, Røe OD, Xu J, Liu L, Gu Y, Guo R, Yin Y, Shu Y, Chen X. A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy. Drug Des Devel Ther 2016;10:241-58. [PMID: 26966350 DOI: 10.2147/DDDT.S88743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
10 Ao S, Wang Y, Song Q, Ye Y, Lyu G. Current status and future perspectives on neoadjuvant therapy in gastric cancer. Chin J Cancer Res 2021;33:181-92. [PMID: 34158738 DOI: 10.21147/j.issn.1000-9604.2021.02.06] [Reference Citation Analysis]
11 McNamara MJ, Rybicki LA, Sohal D, Allende DS, Videtic GM, Rodriguez CP, Stephans KL, Murthy SC, Raja S, Raymond D, Ives DI, Bodmann JW, Adelstein DJ. The relationship between pathologic nodal disease and residual tumor viability after induction chemotherapy in patients with locally advanced esophageal adenocarcinoma receiving a tri-modality regimen. J Gastrointest Oncol 2016;7:196-205. [PMID: 27034786 DOI: 10.3978/j.issn.2078-6891.2015.097] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Batista TP, de Mendonça LM, Fassizoli-Fonte AL. The role of perioperative radiotherapy in gastric cancer. Oncol Rev 2012;6:e23. [PMID: 25992221 DOI: 10.4081/oncol.2012.e23] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
13 Tokunaga M, Sato Y, Nakagawa M, Aburatani T, Matsuyama T, Nakajima Y, Kinugasa Y. Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives. Surg Today. 2020;50:30-37. [PMID: 31612329 DOI: 10.1007/s00595-019-01896-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
14 Kauppila JH, Ohtonen P, Rantanen T, Tyrväinen T, Toikkanen V, Pääaho M, Valtola A, Räsänen J, Kallio R, Sihvo E, Saarnio J, Karttunen TJ, Pohjanen VM, Ristimäki A, Laine S, Kokkola A. Cohort profile: gastric cancer in the population-based, Finnish National Esophago-Gastric Cancer Cohort (FINEGO) Study. BMJ Open 2020;10:e039574. [PMID: 33067296 DOI: 10.1136/bmjopen-2020-039574] [Reference Citation Analysis]
15 Yen CC, Shan YS, Chao YJ, Liao TK, Chen IS, Huang HY, Liu IT, Yen CJ. Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis. BMC Cancer 2021;21:796. [PMID: 34243732 DOI: 10.1186/s12885-021-08487-z] [Reference Citation Analysis]
16 Zhang Y, Yu J. The role of MRI in the diagnosis and treatment of gastric cancer. Diagn Interv Radiol 2020;26:176-82. [PMID: 32209504 DOI: 10.5152/dir.2019.19375] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
17 Schneider PM, Eshmuminov D, Rordorf T, Vetter D, Veit-Haibach P, Weber A, Bauerfeind P, Samaras P, Lehmann K. 18FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study. BMC Cancer 2018;18:548. [PMID: 29743108 DOI: 10.1186/s12885-018-4477-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
18 Yamamoto M, Rashid OM, Wong J. Surgical management of gastric cancer: the East vs. West perspective. J Gastrointest Oncol. 2015;6:79-88. [PMID: 25642341 DOI: 10.3978/j.issn.2078-6891.2014.097] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
19 Atay SM, Blum M, Sepesi B. Adjuvant chemotherapy following trimodality therapy for esophageal carcinoma-Is the evidence sufficient? J Thorac Dis 2017;9:3626-9. [PMID: 29268359 DOI: 10.21037/jtd.2017.09.68] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 Gong W, Zhao L, Dong Z, Dou Y, Liu Y, Ma C, Qu X. After neoadjuvant chemotherapy platelet/lymphocyte ratios negatively correlate with prognosis in gastric cancer patients. J Clin Lab Anal 2018;32:e22364. [PMID: 29251364 DOI: 10.1002/jcla.22364] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
21 Personeni N, Baretti M, Bozzarelli S, Spaggiari P, Rubino L, Tronconi MC, Fumagalli Romario U, Rosati R, Giordano L, Roncalli M, Santoro A, Rimassa L. Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. Gastric Cancer 2017;20:428-37. [PMID: 27530622 DOI: 10.1007/s10120-016-0625-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
22 Mazzei MA, Di Giacomo L, Bagnacci G, Nardone V, Gentili F, Lucii G, Tini P, Marrelli D, Morgagni P, Mura G, Baiocchi GL, Pittiani F, Volterrani L, Roviello F. Delta-radiomics and response to neoadjuvant treatment in locally advanced gastric cancer-a multicenter study of GIRCG (Italian Research Group for Gastric Cancer). Quant Imaging Med Surg 2021;11:2376-87. [PMID: 34079708 DOI: 10.21037/qims-20-683] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Dassen AE, Bernards N, Lemmens VE, van de Wouw YA, Bosscha K, Creemers GJ, Pruijt HJ. Phase II study of docetaxel, cisplatin and capecitabine as preoperative chemotherapy in resectable gastric cancer. World J Gastrointest Surg 2016;8:706-12. [PMID: 27830043 DOI: 10.4240/wjgs.v8.i10.706] [Reference Citation Analysis]
24 Sisic L, Vallböhmer D, Stoecklein NH, Blank S, Schmidt T, Driemel C, Möhlendick B, Knoefel WT, Odenthal M, Ott K. Serum microRNA profiles as prognostic or predictive markers in the multimodality treatment of patients with gastric cancer. Oncol Lett 2015;10:869-74. [PMID: 26622585 DOI: 10.3892/ol.2015.3341] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
25 Harada K, Baba H, Ajani JA. Recent trend in gastric cancer treatment in the USA. J Cancer Metastasis Treat 2018;4:18. [PMID: 34113719 DOI: 10.20517/2394-4722.2017.74] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Laxague F, Schlottmann F. Esophagogastric junction adenocarcinoma: Preoperative chemoradiation or perioperative chemotherapy? World J Clin Oncol 2021;12:557-64. [PMID: 34367928 DOI: 10.5306/wjco.v12.i7.557] [Reference Citation Analysis]
27 Yuan SQ, Nie RC, Chen S, Chen XJ, Chen YM, Xu LP, Yang LF, Zhou ZW, Peng JS, Chen YB. Selective Gastric Cancer Patients with Peritoneal Seeding Benefit from Gastrectomy after Palliative Chemotherapy: A Propensity Score Matching Analysis. J Cancer 2017;8:2231-7. [PMID: 28819425 DOI: 10.7150/jca.18932] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
28 Svensson MC, Warfvinge CF, Fristedt R, Hedner C, Borg D, Eberhard J, Micke P, Nodin B, Leandersson K, Jirström K. The integrative clinical impact of tumor-infiltrating T lymphocytes and NK cells in relation to B lymphocyte and plasma cell density in esophageal and gastric adenocarcinoma. Oncotarget 2017;8:72108-26. [PMID: 29069772 DOI: 10.18632/oncotarget.19437] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
29 Heger U, Bader F, Lordick F, Burian M, Langer R, Dobritz M, Blank S, Bruckner T, Becker K, Herrmann K. Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis. Gastric Cancer. 2013;Sep 1; Epub ahead of print. [PMID: 23996162 DOI: 10.1007/s10120-013-0296-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
30 Li J, Ma S. History and current situation of neoadjuvant treatment for locally advanced esophageal cancer. Thorac Cancer 2021;12:2293-9. [PMID: 34254738 DOI: 10.1111/1759-7714.14069] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Moremen JR, Skopelja EN, Ceppa DP. The role of induction therapy. J Thorac Dis 2014;6 Suppl 3:S309-13. [PMID: 24876935 DOI: 10.3978/j.issn.2072-1439.2014.03.10] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
32 Nakajima T, Fujii M. What make differences in the outcome of adjuvant treatments for resected gastric cancer? World J Gastroenterol 2014;20:11567-73. [PMID: 25206264 DOI: 10.3748/wjg.v20.i33.11567] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
33 Smyth EC. Regorafenib in gastric cancer. Transl Gastroenterol Hepatol 2017;2:16. [PMID: 28447051 DOI: 10.21037/tgh.2017.01.07] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Sbitti Y, Essaidi I, Debbagh A, Kadiri H, Oukabli M, Moussaid Y, Slimani K, Fetohi M, Elkaoui H, Albouzidi A, Mahi M, Ali AA, Ichou M, Errihani H. Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma? World J Surg Oncol 2011;9:112. [PMID: 21955806 DOI: 10.1186/1477-7819-9-112] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
35 Yin S, Wang P, Xu X, Tan Y, Huang J, Xu H. The optimal strategy of multimodality therapies for resectable gastric cancer: evidence from a network meta-analysis. J Cancer. 2019;10:3094-3101. [PMID: 31289579 DOI: 10.7150/jca.30456] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 León-Espinoza C, López-Mozos F, Marti-Obiol R, Garces-Albir M, Ortega-Serrano J. "Magic" of our gastric cancer results on perioperative chemotherapy. World J Gastrointest Pathophysiol 2016;7:283-7. [PMID: 27574566 DOI: 10.4291/wjgp.v7.i3.283] [Reference Citation Analysis]
37 Zhao Q, Chen S, Feng JF. A novel inflammation-based prognostic index for patients with esophageal squamous cell carcinoma: neutrophil lymphocyte ratio/albumin ratio. Oncotarget 2017;8:103535-42. [PMID: 29262582 DOI: 10.18632/oncotarget.21989] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
38 Koch OO, Weitzendorfer M, Varga M, Tschoner A, Partl R, Perathoner A, Gehwolf P, Kapp KS, Függer R, Öfner D, Emmanuel K. Perioperative chemotherapy versus neoadjuvant chemoradiation for patients with adenocarcinoma of the distal esophagus in Austria: a retrospective analysis. World J Surg Oncol 2019;17:146. [PMID: 31426805 DOI: 10.1186/s12957-019-1693-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Li J, Zhao Q, Ge X, Song Y, Tian Y, Wang S, Liu M, Qiao X. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis. BMC Surg 2021;21:137. [PMID: 33731072 DOI: 10.1186/s12893-021-01136-z] [Reference Citation Analysis]
40 Buergy D, Lohr F, Baack T, Siebenlist K, Haneder S, Michaely H, Wenz F, Boda-Heggemann J. Radiotherapy for tumors of the stomach and gastroesophageal junction--a review of its role in multimodal therapy. Radiat Oncol. 2012;7:192. [PMID: 23157945 DOI: 10.1186/1748-717x-7-192] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
41 Zhu YT, Chen XZ, Chen Y, Zhou YW, Tang LS, Luo DY, Li Q, Qiu M, Wang X, Cao D, Yang Y, Shen YL, Li ZP, Bi F, Liu JY, Gou HF. Chemoradiotherapy Is Inferior to Chemotherapy Alone in Adjuvant Setting for Signet Ring Cell Containing Gastric Cancer. Front Oncol 2020;10:570268. [PMID: 33324548 DOI: 10.3389/fonc.2020.570268] [Reference Citation Analysis]
42 Biondi A, Lirosi MC, D'Ugo D, Fico V, Ricci R, Santullo F, Rizzuto A, Cananzi FC, Persiani R. Neo-adjuvant chemo(radio)therapy in gastric cancer: Current status and future perspectives. World J Gastrointest Oncol 2015;7:389-400. [PMID: 26690252 DOI: 10.4251/wjgo.v7.i12.389] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
43 Sun LB, Zhao GJ, Ding DY, Song B, Hou RZ, Li YC. Comparison between better and poorly differentiated locally advanced gastric cancer in preoperative chemotherapy: a retrospective, comparative study at a single tertiary care institute. World J Surg Oncol. 2014;12:280. [PMID: 25200958 DOI: 10.1186/1477-7819-12-280] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
44 Tang C, Feng W, Bao Y, Chen C. Maintenance Chemotherapy with S-1 Following SOX Regimen Chemotherapy Improves Prognosis of Stage 3 Gastric Cancer After D2 Gastrectomy: A 5-Year Analysis. Onco Targets Ther 2020;13:12661-6. [PMID: 33324076 DOI: 10.2147/OTT.S271884] [Reference Citation Analysis]
45 Moehler M, Gockel I, Roessler HP, Arnold D, Trarbach T, Thomaidis T, Klautke G, Rödel C, Brenner B, Lang H. Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction. BMC Cancer. 2013;13:75. [PMID: 23394629 DOI: 10.1186/1471-2407-13-75] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
46 Sohda M, Saito H, Kuriyama K, Yoshida T, Kumakura Y, Honjyo H, Hara K, Ozawa D, Suzuki S, Tanaka N, Sakai M, Miyazaki T, Fukuchi M, Kuwano H. Post-esophagectomy Adjuvant Chemotherapy Benefits Esophageal Cancer Patients. In Vivo 2019;33:501-6. [PMID: 30804133 DOI: 10.21873/invivo.11502] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
47 Miao ZF, Liu XY, Wang ZN, Zhao TT, Xu YY, Song YX, Huang JY, Xu H, Xu HM. Effect of neoadjuvant chemotherapy in patients with gastric cancer: a PRISMA-compliant systematic review and meta-analysis. BMC Cancer. 2018;18:118. [PMID: 29385994 DOI: 10.1186/s12885-018-4027-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
48 Ashraf N, Hoffe S, Kim R. Locally advanced gastroesophageal junction tumor: a treatment dilemma. Oncologist 2015;20:134-42. [PMID: 25561508 DOI: 10.1634/theoncologist.2014-0377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
49 Wang K, Ren Y, Ma Z, Li F, Cheng X, Xiao J, Zhang S, Yu Z, Yang H, Zhou H, Li Y, Liu H, Jiao ZY. Docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT) as preoperative and postoperative chemotherapy compared with surgery followed by chemotherapy for patients with locally advanced gastric cancer: a propensity score-based analysis. Cancer Manag Res 2019;11:3009-20. [PMID: 31114348 DOI: 10.2147/CMAR.S200883] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 4.5] [Reference Citation Analysis]
50 Münch S, Habermehl D, Agha A, Belka C, Combs SE, Eckel R, Friess H, Gerbes A, Nüssler NC, Schepp W, Schmid RM, Schmitt W, Schubert-Fritschle G, Weber B, Werner J, Engel J. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry. Strahlenther Onkol 2018;194:125-35. [PMID: 29071366 DOI: 10.1007/s00066-017-1225-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
51 Terashima M, Iwasaki Y, Mizusawa J, Katayama H, Nakamura K, Katai H, Yoshikawa T, Ito Y, Kaji M, Kimura Y, Hirao M, Yamada M, Kurita A, Takagi M, Boku N, Sano T, Sasako M;  Stomach Cancer Study Group;  Japan Clinical Oncology Group. Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501). Gastric Cancer. 2019;22:1044-1052. [PMID: 30827001 DOI: 10.1007/s10120-019-00941-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 16.0] [Reference Citation Analysis]
52 Mazzei MA, Bagnacci G, Gentili F, Capitoni I, Mura G, Marrelli D, Petrioli R, Brunese L, Cappabianca S, Catarci M, Degiuli M, De Manzoni G, De Prizio M, Donini A, Romario UF, Funicelli L, Laghi A, Minetti G, Morgagni P, Petrella E, Pittiani F, Rausei S, Romanini L, Rosati R, Ianora AAS, Tiberio GAM, Volterrani L, Roviello F, Grassi R. Structured and shared CT radiological report of gastric cancer: a consensus proposal by the Italian Research Group for Gastric Cancer (GIRCG) and the Italian Society of Medical and Interventional Radiology (SIRM). Eur Radiol 2021. [PMID: 34383148 DOI: 10.1007/s00330-021-08205-0] [Reference Citation Analysis]
53 Sun L, Zhang H, Wu K. Esophageal Cancer: Current Options for Therapeutic Management. Gastrointest Tumors 2014;1:105-13. [PMID: 26674591 DOI: 10.1159/000362907] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
54 Shrikhande SV, Barreto SG, Talole SD, Vinchurkar K, Annaiah S, Suradkar K, Mehta S, Goel M. D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy. World J Surg Oncol. 2013;11:31. [PMID: 23375104 DOI: 10.1186/1477-7819-11-31] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
55 Yu Y, Ma X, Zhang Y, Zhang Y, Ying J, Zhang W, Zhong Q, Zhou A, Zeng Y. Changes in Expression of Multiple Checkpoint Molecules and Infiltration of Tumor Immune Cells after Neoadjuvant Chemotherapy in Gastric Cancer. J Cancer 2019;10:2754-63. [PMID: 31258783 DOI: 10.7150/jca.31755] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
56 Miao RL, Wu AW. Towards personalized perioperative treatment for advanced gastric cancer. World J Gastroenterol. 2014;20:11586-11594. [PMID: 25206266 DOI: 10.3748/wjg.v20.i33.11586] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
57 Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10:643-655. [PMID: 24061039 DOI: 10.1038/nrclinonc.2013.170] [Cited by in Crossref: 249] [Cited by in F6Publishing: 227] [Article Influence: 31.1] [Reference Citation Analysis]
58 Franco P, Arcadipane F, Strignano P, Spadi R, Trino E, Martini S, Iorio GC, Satolli MA, Airoldi M, Romagnoli R, Camandona M, Ricardi U. Pre-operative treatments for adenocarcinoma of the lower oesophagus and gastro-oesophageal junction: a review of the current evidence from randomized trials. Med Oncol 2017;34:40. [PMID: 28176241 DOI: 10.1007/s12032-017-0898-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
59 Tu CC, Hsu PK. The frontline of esophageal cancer treatment: questions to be asked and answered. Ann Transl Med 2018;6:83. [PMID: 29666806 DOI: 10.21037/atm.2017.10.31] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
60 Roviello G, Polom K, Petrioli R, Marano L, Marrelli D, Paganini G, Savelli V, Generali D, De Franco L, Ravelli A, Roviello F. Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. Tumour Biol 2016;37:127-40. [PMID: 26566626 DOI: 10.1007/s13277-015-4408-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
61 Vošmik M, Laco J, Sirák I, Dvořák J, Lochman P, Hodek M, Malá P, Rejchrt S, Repák R, Leško M, Ferko A, Ryška A, Melichar B, Petera J. Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery. Pathol Oncol Res 2018;24:373-83. [PMID: 28550507 DOI: 10.1007/s12253-017-0253-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
62 Reim D, Strobl AN, Buchner C, Schirren R, Mueller W, Luppa P, Ankerst DP, Friess H, Novotny A. Perioperative transfusion of leukocyte depleted blood products in gastric cancer patients negatively influences oncologic outcome: A retrospective propensity score weighted analysis on 610 curatively resected gastric cancer patients. Medicine (Baltimore) 2016;95:e4322. [PMID: 27442682 DOI: 10.1097/MD.0000000000004322] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
63 Li G, Zhang Z, Ma X, Zhu J, Cai G. Postoperative chemoradiotherapy combined with epirubicin-based triplet chemotherapy for locally advanced adenocarcinoma of the stomach or gastroesophageal junction. PLoS One 2013;8:e54233. [PMID: 23372688 DOI: 10.1371/journal.pone.0054233] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
64 Zurlo IV, Basso M, Strippoli A, Calegari MA, Orlandi A, Cassano A, Di Salvatore M, Garufi G, Bria E, Tortora G, Barone C, Pozzo C. Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren's Classification in Pan-Cancer Analysis Era? Cancers (Basel) 2020;12:E1749. [PMID: 32630186 DOI: 10.3390/cancers12071749] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
65 Hoeppner J, Lordick F, Brunner T, Glatz T, Bronsert P, Röthling N, Schmoor C, Lorenz D, Ell C, Hopt UT, Siewert JR. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer 2016;16:503. [PMID: 27435280 DOI: 10.1186/s12885-016-2564-y] [Cited by in Crossref: 103] [Cited by in F6Publishing: 81] [Article Influence: 20.6] [Reference Citation Analysis]
66 Coccolini F, Montori G, Ceresoli M, Cima S, Valli MC, Nita GE, Heyer A, Catena F, Ansaloni L. Advanced gastric cancer: What we know and what we still have to learn. World J Gastroenterol. 2016;22:1139-1159. [PMID: 26811653 DOI: 10.3748/wjg.v22.i3.1139] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
67 Steber C, Hughes RT, McTyre ER, Soike M, Farris M, Levine BJ, Pasche B, Levine E, Blackstock AW. Cisplatin/5-Fluorouracil (5-FU) Versus Carboplatin/Paclitaxel Chemoradiotherapy as Definitive or Pre-Operative Treatment of Esophageal Cancer. Cureus 2021;13:e12574. [PMID: 33575139 DOI: 10.7759/cureus.12574] [Reference Citation Analysis]
68 Drake J, Tauer K, Portnoy D, Weksler B. Adjuvant chemotherapy is associated with improved survival in patients with nodal metastases after neoadjuvant therapy and esophagectomy. J Thorac Dis 2019;11:2546-54. [PMID: 31372291 DOI: 10.21037/jtd.2019.05.66] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
69 Wang X, Li S, Sun Y, Li K, Shen X, Xue Y, Liang P, Li G, Chen L, Zhao Q, Li G, Fu W, Liang H, Xin H, Suo J, Fang X, Zheng Z, Xu Z, Chen H, Zhou Y, He Y, Huang H, Zhu L, Yang K, Ji J, Ye Y, Zhang Z, Li F, Wang X, Tian Y, Park S, Chen L. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial. BMC Cancer 2021;21:20. [PMID: 33402102 DOI: 10.1186/s12885-020-07764-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
70 Lorenzen S, Pauligk C, Homann N, Schmalenberg H, Jäger E, Al-Batran SE. Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer. Br J Cancer. 2013;108:519-526. [PMID: 23322206 DOI: 10.1038/bjc.2012.588] [Cited by in Crossref: 60] [Cited by in F6Publishing: 43] [Article Influence: 7.5] [Reference Citation Analysis]
71 Samalin E, Ychou M. Neoadjuvant therapy for gastroesophageal adenocarcinoma. World J Clin Oncol 2016;7:284-92. [PMID: 27298768 DOI: 10.5306/wjco.v7.i3.284] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
72 Wang X, Li X, Zhou N, Zhong D, Bai C, Zhao L. Graded histologic response after neoadjuvant chemotherapy is an optimal criterion for treatment change in patients with locally advanced gastric cancer. Ann Transl Med 2019;7:546. [PMID: 31807528 DOI: 10.21037/atm.2019.09.82] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
73 Ge L, Wang HJ, Yin D, Lei C, Zhu JF, Cai XH, Zhang GQ. Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: a meta-analysis. World J Gastroenterol. 2012;18:7384-7393. [PMID: 23326149 DOI: 10.3748/wjg.v18.i48.7384] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
74 Schmidt T, Mönig SP. [Therapeutic approach in oligometastatic gastric and esophageal cancer]. Chirurg 2017;88:1024-32. [PMID: 29098307 DOI: 10.1007/s00104-017-0548-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
75 Lichthardt S, Kerscher A, Dietz UA, Jurowich C, Kunzmann V, von Rahden BH, Germer CT, Wiegering A. Original article: role of adjuvant chemotherapy in a perioperative chemotherapy regimen for gastric cancer. BMC Cancer 2016;16:650. [PMID: 27538392 DOI: 10.1186/s12885-016-2708-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
76 Hernando-Cubero J, Matos-García I, Alonso-Orduña V, Capdevila J. The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed. J Gastrointest Cancer 2017;48:135-47. [PMID: 28397102 DOI: 10.1007/s12029-017-9946-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
77 Ju MR, Karalis JD, Blackwell JM, Mansour JC, Polanco PM, Augustine M, Yopp AC, Zeh HJ 3rd, Wang SC, Porembka MR. Inaccurate Clinical Stage Is Common for Gastric Adenocarcinoma and Is Associated with Undertreatment and Worse Outcomes. Ann Surg Oncol 2021;28:2831-43. [PMID: 33389294 DOI: 10.1245/s10434-020-09403-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
78 Yu YJ, Sun WJ, Lu MD, Wang FH, Qi DS, Zhang Y, Li PH, Huang H, You T, Zheng ZQ. Efficacy of docetaxel combined with oxaliplatin and fluorouracil against stage III/IV gastric cancer. World J Gastroenterol 2014;20:18413-9. [PMID: 25561810 DOI: 10.3748/wjg.v20.i48.18413] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
79 Ott K, Blank S, Ruspi L, Bauer M, Sisic L, Schmidt T. Prognostic impact of nodal status and therapeutic implications. Transl Gastroenterol Hepatol. 2017;2:15. [PMID: 28447050 DOI: 10.21037/tgh.2017.01.10] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
80 Ramachandra, Goel V, Raju K, Rao TS, Patnaik, Nusrath, Santa, Murthy S. Prospective Randomized Controlled Study Comparing Primary Surgery Versus Neoadjuvant Chemotherapy Followed by Surgery in Gastric Carcinoma. Indian J Surg Oncol 2019;10:245-50. [PMID: 31168243 DOI: 10.1007/s13193-019-00908-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Wang L, Zhang Y, Chen Y, Tan J, Wang L, Zhang J, Yang C, Ma Q, Ge Y, Xu Z, Pan Z, Du L, Yan F, Yao W, Zhang H. The Performance of a Dual-Energy CT Derived Radiomics Model in Differentiating Serosal Invasion for Advanced Gastric Cancer Patients After Neoadjuvant Chemotherapy: Iodine Map Combined With 120-kV Equivalent Mixed Images. Front Oncol 2020;10:562945. [PMID: 33585186 DOI: 10.3389/fonc.2020.562945] [Reference Citation Analysis]
82 Moorcraft SY, Fontana E, Cunningham D, Peckitt C, Waddell T, Smyth EC, Allum W, Thompson J, Rao S, Watkins D, Starling N, Chau I. Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study. BMC Cancer 2016;16:112. [PMID: 26883815 DOI: 10.1186/s12885-016-2145-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
83 Taylor LJ, Greenberg CC, Lidor AO, Leverson GE, Maloney JD, Macke RA. Utilization of surgical treatment for local and locoregional esophageal cancer: Analysis of the National Cancer Data Base. Cancer 2017;123:410-9. [PMID: 27680893 DOI: 10.1002/cncr.30368] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
84 Mazzei MA, Bagnacci G, Gentili F, Nigri A, Pelini V, Vindigni C, Mazzei FG, Baiocchi GL, Pittiani F, Morgagni P, Petrella E, Mura G, Verdelli B, Bencivenga M, Giacopuzzi S, Marrelli D, Roviello F, Volterrani L. Gastric Cancer Maximum Tumour Diameter Reduction Rate at CT Examination as a Radiological Index for Predicting Histopathological Regression after Neoadjuvant Treatment: A Multicentre GIRCG Study. Gastroenterol Res Pract 2018;2018:1794524. [PMID: 29736166 DOI: 10.1155/2018/1794524] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
85 Alsina M, Miquel JM, Diez M, Castro S, Tabernero J. How I treat gastric adenocarcinoma. ESMO Open. 2019;4:e000521. [PMID: 31354966 DOI: 10.1136/esmoopen-2019-000521] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
86 Mokdad AA, Yopp AC, Polanco PM, Mansour JC, Reznik SI, Heitjan DF, Choti MA, Minter RR, Wang SC, Porembka MR. Adjuvant Chemotherapy vs Postoperative Observation Following Preoperative Chemoradiotherapy and Resection in Gastroesophageal Cancer: A Propensity Score-Matched Analysis. JAMA Oncol 2018;4:31-8. [PMID: 28975352 DOI: 10.1001/jamaoncol.2017.2805] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 15.0] [Reference Citation Analysis]
87 Lee JH, Kim KM, Cheong JH, Noh SH. Current management and future strategies of gastric cancer. Yonsei Med J 2012;53:248-57. [PMID: 22318810 DOI: 10.3349/ymj.2012.53.2.248] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
88 Tao CJ, Lin G, Xu YP, Mao WM. Predicting the Response of Neoadjuvant Therapy for Patients with Esophageal Carcinoma: an In-depth Literature Review. J Cancer 2015;6:1179-86. [PMID: 26516367 DOI: 10.7150/jca.12346] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
89 Triantafyllou T, Wijnhoven BPL. Current status of esophageal cancer treatment. Chin J Cancer Res 2020;32:271-86. [PMID: 32694894 DOI: 10.21147/j.issn.1000-9604.2020.03.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
90 Le Roy B, Pereira B, Bouteloup C, Costes F, Richard R, Selvy M, Pétorin C, Gagnière J, Futier E, Slim K, Meunier B, Mabrut JY, Mariette C, Pezet D. Effect of prehabilitation in gastro-oesophageal adenocarcinoma: study protocol of a multicentric, randomised, control trial-the PREHAB study. BMJ Open 2016;6:e012876. [PMID: 27927660 DOI: 10.1136/bmjopen-2016-012876] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
91 Novotny AR, Reim D, Friess HM, Schuhmacher C. Secondary gastrectomy for stage IV gastroesophageal adenocarcinoma after induction-chemotherapy. Langenbecks Arch Surg 2014;399:773-81. [PMID: 24898674 DOI: 10.1007/s00423-014-1217-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
92 Chen XL, Pu H, Yin LL, Li JR, Li ZL, Chen GW, Hou NY, Li H. CT volumetry for gastric adenocarcinoma: association with lymphovascular invasion and T-stages. Oncotarget 2018;9:12432-42. [PMID: 29552323 DOI: 10.18632/oncotarget.23478] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
93 Cools-Lartigue J, Spicer J, Ferri LE. Current status of management of malignant disease: current management of esophageal cancer. J Gastrointest Surg 2015;19:964-72. [PMID: 25650163 DOI: 10.1007/s11605-014-2701-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
94 Blakely AM, Miner TJ. Surgical considerations in the treatment of gastric cancer. Gastroenterol Clin North Am. 2013;42:337-357. [PMID: 23639644 DOI: 10.1016/j.gtc.2013.01.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
95 Yoshikawa T, Rino Y, Yukawa N, Oshima T, Tsuburaya A, Masuda M. Neoadjuvant chemotherapy for gastric cancer in Japan: a standing position by comparing with adjuvant chemotherapy. Surg Today. 2014;44:11-21. [PMID: 23508452 DOI: 10.1007/s00595-013-0529-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
96 Orditura M, Galizia G, Lieto E, De Vita F, Ciardiello F. Treatment of esophagogastric junction carcinoma: an unsolved debate. World J Gastroenterol 2015;21:4427-31. [PMID: 25914451 DOI: 10.3748/wjg.v21.i15.4427] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
97 Mihmanli M, Ilhan E, Idiz UO, Alemdar A, Demir U. Recent developments and innovations in gastric cancer. World J Gastroenterol 2016;22:4307-20. [PMID: 27158199 DOI: 10.3748/wjg.v22.i17.4307] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 40] [Article Influence: 9.8] [Reference Citation Analysis]
98 Bian D, Qi M, Hu J, Ning Y, Zhou F, Fei K, Zhang P. The comparison of predictive factors regarding prognoses and invasion of thymic neuroendocrine tumors preoperatively and postoperatively. J Thorac Dis 2018;10:1657-69. [PMID: 29707318 DOI: 10.21037/jtd.2018.02.82] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
99 Zhao Q, Lian C, Huo Z, Li M, Liu Y, Fan L, Tan B, Zhao X, Zhang Z, Wang D, Liu Y, Guo H, Yang P, Tian Y, Li Y. The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial. Cancer Med 2020;9:5731-45. [PMID: 32583567 DOI: 10.1002/cam4.3224] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
100 Li LH, Chen ZF, Wang XF, Zhuo SM, Li HS, Jiang WZ, Guan GX, Chen JX. Multiphoton microscopy for tumor regression grading after neoadjuvant treatment for colorectal carcinoma. World J Gastroenterol 2015;21:4210-5. [PMID: 25892870 DOI: 10.3748/wjg.v21.i14.4210] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
101 Manzini G, Henne-Bruns D, Kremer M. Validity of studies suggesting postsurgical chemotherapy for resectable gastric cancer: critical appraisal of randomised trials. BMJ Open Gastroenterol. 2017;4:e000138. [PMID: 29177062 DOI: 10.1136/bmjgast-2017-000138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
102 Zhang CD, Yamashita H, Seto Y. Gastric cancer surgery: historical background and perspective in Western countries versus Japan. Ann Trans Med. 2019;7(18):493. [PMID: 31700929 DOI: 10.21037/atm.2019.08.48] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
103 Keditsu KK, Jiwnani S, Karimundackal G, Pramesh CS. Multimodality management of esophageal cancer. Indian J Surg Oncol. 2013;4:96-104. [PMID: 24426708 DOI: 10.1007/s13193-013-0216-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
104 Hu SB, Liu CH, Wang X, Dong YW, Zhao L, Liu HF, Cao Y, Zhong DR, Liu W, Li YL, Gao WS, Bai CM, Shang ZH, Li XY. Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer. World J Surg Oncol 2019;17:3. [PMID: 30606195 DOI: 10.1186/s12957-018-1534-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
105 Fuentes E, Ahmad R, Hong TS, Clark JW, Kwak EL, Rattner DW, Mullen JT. Adjuvant Therapy Completion Rates in Patients with Gastric Cancer Undergoing Perioperative Chemotherapy Versus a Surgery-First Approach. J Gastrointest Surg 2016;20:172-9; discussion 179. [PMID: 26394879 DOI: 10.1007/s11605-015-2954-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
106 Liu X, Jin J, Cai H, Huang H, Zhao G, Zhou Y, Wu J, Du C, Long Z, Fang Y, Ma M, Li G, Zhou M, Yin J, Zhu X, Zhu J, Sheng W, Huang D, Zhu H, Zhang Z, Lu Q, Xie L, Zhang Z, Wang Y. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT. BMC Cancer 2019;19:606. [PMID: 31221115 DOI: 10.1186/s12885-019-5728-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
107 Chen X, Eads JR, Ammori JB, Kumar AM, Biswas T, Dorth JA. Adjuvant and neoadjuvant options in resectable gastric cancer: is there an optimal treatment approach? Curr Oncol Rep 2015;17:18. [PMID: 25708803 DOI: 10.1007/s11912-015-0442-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
108 Rausei S, Lianos GD. Treatment of Gastric Cancer. Cancers (Basel) 2020;12:E2627. [PMID: 32942552 DOI: 10.3390/cancers12092627] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
109 Yang Y, Yin X, Sheng L, Xu S, Dong L, Liu L. Perioperative chemotherapy more of a benefit for overall survival than adjuvant chemotherapy for operable gastric cancer: an updated Meta-analysis. Sci Rep 2015;5:12850. [PMID: 26242393 DOI: 10.1038/srep12850] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
110 Yu JH, Wang ZZ, Fan YC, Liu MX, Xu K, Zhang N, Yao ZD, Yang H, Zhang CH, Xing JD, Cui M, Su XQ. Comparison of neoadjuvant chemotherapy followed by surgery vs. surgery alone for locally advanced gastric cancer: a meta-analysis. Chin Med J (Engl) 2021;134:1669-80. [PMID: 34397593 DOI: 10.1097/CM9.0000000000001603] [Reference Citation Analysis]
111 Funt SA, Chapman PB. The Role of Neoadjuvant Trials in Drug Development for Solid Tumors. Clin Cancer Res 2016;22:2323-8. [PMID: 26842238 DOI: 10.1158/1078-0432.CCR-15-1961] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
112 Xu W, Beeharry MK, Liu W, Yan M, Zhu Z. Preoperative Chemotherapy for Gastric Cancer: Personal Interventions and Precision Medicine. Biomed Res Int 2016;2016:3923585. [PMID: 28105420 DOI: 10.1155/2016/3923585] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
113 Aytaç E, Aslan F, Çicek B, Erdamar S, Gürses B, Güven K, Falay O, Karahasanoğlu T, Selçukbiricik F, Selek U, Atalar B, Balık E, Tözün N, Rozanes İ, Arıcan A, Hamzaoğlu İ, Baca B, Molinas Mandel N, Saruç M, Göksel S, Demir G, Ağaoğlu F, Yakıcıer C, Özbek U, Özben V, Özyar E, Güner AL, Er Ö, Kaban K, Bölükbaşı Y, Buğra D, Group Tİ. Dealing with the gray zones in the management of gastric cancer: The consensus statement of the İstanbul Group. Turk J Gastroenterol 2019;30:584-98. [PMID: 30541724 DOI: 10.5152/tjg.2018.18737] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Borg D, Hedner C, Nodin B, Larsson A, Johnsson A, Eberhard J, Jirström K. Expression of podocalyxin-like protein is an independent prognostic biomarker in resected esophageal and gastric adenocarcinoma. BMC Clin Pathol 2016;16:13. [PMID: 27478410 DOI: 10.1186/s12907-016-0034-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
115 Agolli L, Nicosia L. Between evidence and new perspectives on the current state of the multimodal approach to gastric cancer: Is there still a role for radiation therapy? World J Gastrointest Oncol. 2018;10:271-281. [PMID: 30254722 DOI: 10.4251/wjgo.v10.i9.271] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
116 Li Z, Shan F, Ying X, Zhang L, Ren H, Li S, Jia Y, Miao R, Xue K, Li Z, Wang Y, Yan C, Zhang Y, Pang F, Ji J. Laparoscopic or open distal gastrectomy after neoadjuvant chemotherapy for advanced gastric cancer: study protocol for a randomised phase II trial. BMJ Open 2018;8:e021633. [PMID: 30099396 DOI: 10.1136/bmjopen-2018-021633] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
117 Smyth E, Zhang S, Cunningham D, Wotherspoon A, Soong R, Peckitt C, Valeri N, Fassan M, Rugge M, Okines A, Allum W, Stenning S, Nankivell M, Langley R, Tan P. Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy. Clin Cancer Res 2017;23:7543-9. [PMID: 28972045 DOI: 10.1158/1078-0432.CCR-16-3142] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Nakayama I, Takahari D, Wakatsuki T, Osumi H, Chin K, Ogura M, Sato T, Suzuki T, Kamiimabeppu D, Ooki A, Suenaga M, Shinozaki E, Yamaguchi K. Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting. ESMO Open 2020;5:e000595. [PMID: 32273288 DOI: 10.1136/esmoopen-2019-000595] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Hosoda K, Niihara M, Ushiku H, Harada H, Sakuraya M, Washio M, Yamashita K, Hiki N. Prevention of intra-thoracic recurrent laryngeal nerve injury with robot-assisted esophagectomy. Langenbecks Arch Surg 2020;405:533-40. [PMID: 32494883 DOI: 10.1007/s00423-020-01904-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Karagkounis G, Squires MH 3rd, Melis M, Poultsides GA, Worhunsky D, Jin LX, Fields RC, Spolverato G, Pawlik TM, Votanopoulos KI, Levine EA, Schmidt C, Bloomston M, Cho CS, Weber S, Masi A, Berman R, Pachter HL, Staley CA, Newman E, Maithel SK, Hatzaras I. Predictors and Prognostic Implications of Perioperative Chemotherapy Completion in Gastric Cancer. J Gastrointest Surg 2017;21:1984-92. [PMID: 28963709 DOI: 10.1007/s11605-017-3594-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
121 Chu LY, Zhou JY, Zhao YX, Ou YT, Yang T, Peng YH, Fang WK, Xu YW, Xie JJ. Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor. Biosci Rep 2021;41:BSR20204117. [PMID: 34085702 DOI: 10.1042/BSR20204117] [Reference Citation Analysis]
122 Zurleni T, Gjoni E, Altomare M, Rausei S. Conversion surgery for gastric cancer patients: A review. World J Gastrointest Oncol 2018;10:398-409. [PMID: 30487951 DOI: 10.4251/wjgo.v10.i11.398] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
123 Fontana E, Smyth EC. Novel targets in the treatment of advanced gastric cancer: a perspective review. Ther Adv Med Oncol. 2016;8:113-125. [PMID: 26929787 DOI: 10.1177/1758834015616935] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
124 Lordick F, Gockel I. Chances, risks and limitations of neoadjuvant therapy in surgical oncology. Innov Surg Sci 2016;1:3-11. [PMID: 31579713 DOI: 10.1515/iss-2016-0004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
125 Kung CH, Jestin Hannan C, Linder G, Johansson J, Nilsson M, Hedberg J, Lindblad M. Impact of surgical resection rate on survival in gastric cancer: nationwide study. BJS Open 2021;5:zraa017. [PMID: 33688944 DOI: 10.1093/bjsopen/zraa017] [Reference Citation Analysis]
126 Ikoma N, Blum M, Estrella JS, Das P, Hofstetter WL, Fournier KF, Mansfield P, Ajani JA, Badgwell BD. Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy. Gastric Cancer 2018;21:74-83. [PMID: 28643144 DOI: 10.1007/s10120-017-0743-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 7.8] [Reference Citation Analysis]
127 Saito T, Kurokawa Y, Takiguchi S, Miyazaki Y, Takahashi T, Yamasaki M, Miyata H, Nakajima K, Mori M, Doki Y. Accuracy of multidetector-row CT in diagnosing lymph node metastasis in patients with gastric cancer. Eur Radiol. 2015;25:368-374. [PMID: 25097136 DOI: 10.1007/s00330-014-3373-9] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
128 Deng W, Yang Z, Dong X, Yu R, Wang W. Conditional survival in patients with esophageal or gastroesophageal junction cancer after receiving various treatment modalities. Cancer Med 2021;10:659-74. [PMID: 33314798 DOI: 10.1002/cam4.3651] [Reference Citation Analysis]
129 Sun Y, Zhang D, Mao M, Lu Y, Jiao N. Roles of p38 and JNK protein kinase pathways activated by compound cantharidin capsules containing serum on proliferation inhibition and apoptosis of human gastric cancer cell line. Exp Ther Med 2017;14:1809-17. [PMID: 28810654 DOI: 10.3892/etm.2017.4704] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
130 Liu Z, Wang Y, Shan F, Ying X, Zhang Y, Li S, Jia Y, Li Z, Ji J. 5-Fu-Based Doublet Regimen in Patients Receiving Perioperative or Postoperative Chemotherapy for Locally Advanced Gastric Cancer: When to Start and How Long Should the Regimen Last? Cancer Manag Res 2021;13:147-61. [PMID: 33469359 DOI: 10.2147/CMAR.S285361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Chon SH, Berlth F, Plum PS, Herbold T, Alakus H, Kleinert R, Moenig SP, Bruns CJ, Hoelscher AH, Meyer HJ. Gastric cancer treatment in the world: Germany. Transl Gastroenterol Hepatol 2017;2:53. [PMID: 28616608 DOI: 10.21037/tgh.2017.05.07] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
132 Che K, Liu F, Wu N, Liu Q, Yuan L, Wei J. Individualized prediction of survival benefits from perioperative chemoradiotherapy for patients with resectable gastric cancer. Cancer Med 2020;9:7137-50. [PMID: 32810384 DOI: 10.1002/cam4.3350] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
133 Foo M, Leong T. Adjuvant therapy for gastric cancer: current and future directions. World J Gastroenterol 2014;20:13718-27. [PMID: 25320509 DOI: 10.3748/wjg.v20.i38.13718] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
134 Xiang M, Chang DT, Heestand GM, Pollom EL. Survival after neoadjuvant approaches to gastroesophageal junction cancer. Gastric Cancer 2020;23:175-83. [PMID: 31230228 DOI: 10.1007/s10120-019-00980-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
135 Procopio F, Marano S, Gentile D, Da Roit A, Basato S, Riva P, De Vita F, Torzilli G, Castoro C. Management of Liver Oligometastatic Esophageal Cancer: Overview and Critical Analysis of the Different Loco-Regional Treatments. Cancers (Basel) 2019;12:E20. [PMID: 31861604 DOI: 10.3390/cancers12010020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
136 Zheng Y, Wang Z, Yan C, Yan M, Hou Z, Zheng R, Zhu Z, Li C. Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma. Ann Transl Med 2020;8:1684. [PMID: 33490196 DOI: 10.21037/atm-20-7802] [Reference Citation Analysis]
137 Ikoma N, Lee JH, Bhutani MS, Ross WA, Weston B, Chiang YJ, Blum MA, Sagebiel T, Devine CE, Matamoros A Jr, Fournier K, Mansfield P, Ajani JA, Badgwell BD. Preoperative accuracy of gastric cancer staging in patient selection for preoperative therapy: race may affect accuracy of endoscopic ultrasonography. J Gastrointest Oncol 2017;8:1009-17. [PMID: 29299361 DOI: 10.21037/jgo.2017.04.04] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
138 Lorenzen S, Biederstädt A, Ronellenfitsch U, Reißfelder C, Mönig S, Wenz F, Pauligk C, Walker M, Al-Batran SE, Haller B, Hofheinz RD. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV. BMC Cancer 2020;20:886. [PMID: 32933498 DOI: 10.1186/s12885-020-07388-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
139 Leiting JL, Grotz TE. Advancements and challenges in treating advanced gastric cancer in the West. World J Gastrointest Oncol 2019;11:652-64. [PMID: 31558971 DOI: 10.4251/wjgo.v11.i9.652] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
140 Liu Y, Zhang KC, Huang XH, Xi HQ, Gao YH, Liang WQ, Wang XX, Chen L. Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes. World J Gastroenterol. 2018;24:257-265. [PMID: 29375211 DOI: 10.3748/wjg.v24.i2.257] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
141 Wang T, Chen Y, Zhao L, Zhou H, Wu C, Zhang X, Zhou A, Jin J, Zhao D. The Effect of Neoadjuvant Therapies for Patients with Locally Advanced Gastric Cancer: A Propensity Score Matching Study. J Cancer 2021;12:379-86. [PMID: 33391434 DOI: 10.7150/jca.46847] [Reference Citation Analysis]
142 Mrena J, Mattila A, Böhm J, Jantunen I, Kellokumpu I. Surgical care quality and oncologic outcome after D2 gastrectomy for gastric cancer. World J Gastroenterol 2015;21:13294-301. [PMID: 26715812 DOI: 10.3748/wjg.v21.i47.13294] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
143 Hoang T, Park M, Hiyama D, Dayyani F. Predictors of outcomes in patients with gastric cancer treated with contemporary multimodality strategies-a single institution experience. J Gastrointest Oncol 2020;11:411-20. [PMID: 32399281 DOI: 10.21037/jgo.2019.01.08] [Reference Citation Analysis]
144 Jain VK, Cunningham D, Rao S. Chemotherapy for operable gastric cancer: current perspectives. Indian J Surg Oncol. 2011;2:334-342. [PMID: 23204792 DOI: 10.1007/s13193-012-0139-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
145 Dreyfuss AD, Barsky AR, Wileyto EP, Eads JR, Kucharczuk JC, Williams NN, Karasic TB, Metz JM, Ben-Josef E, Plastaras JP, Wojcieszynski AP. The efficacy and safety of definitive concurrent chemoradiotherapy for non-operable esophageal cancer. Cancer Med 2021;10:1275-88. [PMID: 33474812 DOI: 10.1002/cam4.3724] [Reference Citation Analysis]
146 Won E, Ilson DH. Management of localized esophageal cancer in the older patient. Oncologist 2014;19:367-74. [PMID: 24664485 DOI: 10.1634/theoncologist.2013-0178] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
147 Deng J, Wang C, Xiang M, Liu F, Liu Y, Zhao K. Meta-analysis of postoperative efficacy in patients receiving chemoradiotherapy followed by surgery for resectable esophageal carcinoma. Diagn Pathol. 2014;9:151. [PMID: 25030066 DOI: 10.1186/1746-1596-9-151] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
148 Shum H, Rajdev L. Multimodality management of resectable gastric cancer: A review. World J Gastrointest Oncol. 2014;6:393-402. [PMID: 25320655 DOI: 10.4251/wjgo.v6.i10.393] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
149 Haag GM, Stocker G, Quidde J, Jaeger D, Lordick F. Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer - the multinational MATEO study. BMC Cancer 2017;17:509. [PMID: 28760152 DOI: 10.1186/s12885-017-3497-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
150 Shah RD, Cassano AD, Neifeld JP. Neoadjuvant therapy for esophageal cancer. World J Gastrointest Oncol 2014;6:403-6. [PMID: 25320656 DOI: 10.4251/wjgo.v6.i10.403] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
151 Stroes CI, Schokker S, Molenaar RJ, Mathôt RAA, Bijlsma MF, van der Woude SO, Belo Pereira JP, Hooijer GKJ, Verhoeven RHA, Cats A, Grootscholten C, van Sandick JW, Creemers GJ, Nieuwenhuijzen GAP, Haj Mohammad N, Ruurda JP, Meijer SL, Hulshof MCCM, van Berge Henegouwen MI, van Laarhoven HWM. A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. Cancers (Basel) 2021;13:839. [PMID: 33671266 DOI: 10.3390/cancers13040839] [Reference Citation Analysis]
152 Jürgensen C, Brand J, Nothnagel M, Arlt A, Neser F, Habeck JO, Schreiber S, Stölzel U, Zeitz M, Hampe J. Prognostic relevance of gastric cancer staging by endoscopic ultrasound. Surg Endosc. 2013;27:1124-1129. [PMID: 23052533 DOI: 10.1007/s00464-012-2558-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
153 Wang X, Sweigert P, Eguia E, Varsnik MA, Renz CR, Terrasse WA, Gauthier M, Aranha G, Knab LM, Abood G. Impact of angiotensin system inhibitors on esophageal cancer survival. Surg Open Sci 2021;3:34-8. [PMID: 33554099 DOI: 10.1016/j.sopen.2020.08.001] [Reference Citation Analysis]
154 Pyo JH, Lee H, Min YW, Min BH, Lee JH, Kim KM, Yoo H, Ahn S, Kim JJ. Indication for endoscopic treatment based on the risk of lymph node metastasis in patients with Siewert type II/III early gastric cancer. Gastric Cancer 2018;21:672-9. [PMID: 29243195 DOI: 10.1007/s10120-017-0789-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
155 Giuliani A, Miccini M, Basso L. Extent of lymphadenectomy and perioperative therapies: two open issues in gastric cancer. World J Gastroenterol 2014;20:3889-904. [PMID: 24744579 DOI: 10.3748/wjg.v20.i14.3889] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
156 Ji KSY, Thomas SM, Roman SA, Czito B, Anderson KL Jr, Frakes J, Adam MA, Sosa JA, Robinson TJ. Low- vs. High-Dose Neoadjuvant Radiation in Trimodality Treatment of Locally Advanced Esophageal Cancer. J Gastrointest Surg. 2019;23:885-894. [PMID: 30374818 DOI: 10.1007/s11605-018-4007-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
157 Beeharry MK, Ni ZT, Yang ZY, Zheng YN, Feng RH, Liu WT, Yan C, Yao XX, Li C, Yan M, Zhu ZG. Study protocol of a multicenter phase III randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastric cancer (AGC): dragon II trial. BMC Cancer 2020;20:224. [PMID: 32183736 DOI: 10.1186/s12885-020-6701-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
158 Donohoe CL, Reynolds JV. Neoadjuvant treatment of locally advanced esophageal and junctional cancer: the evidence-base, current key questions and clinical trials. J Thorac Dis 2017;9:S697-704. [PMID: 28815065 DOI: 10.21037/jtd.2017.03.159] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
159 Greally M, Ku GY. Adjuvant chemotherapy for poor pathologic response after pre-operative chemoradiation in esophageal cancer: infeasible and illogical. J Thorac Dis 2019;11:S1855-60. [PMID: 31632768 DOI: 10.21037/jtd.2019.08.116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
160 Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z, Fassan M, Rugge M, Valeri N, Okines A, Hewish M, Allum W, Stenning S, Nankivell M, Langley R, Cunningham D. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol. 2017;3:1197-1203. [PMID: 28241187 DOI: 10.1001/jamaoncol.2016.6762] [Cited by in Crossref: 190] [Cited by in F6Publishing: 178] [Article Influence: 47.5] [Reference Citation Analysis]
161 Kumar T, Pai E, Singh R, Francis NJ, Pandey M. Neoadjuvant strategies in resectable carcinoma esophagus: a meta-analysis of randomized trials. World J Surg Oncol 2020;18:59. [PMID: 32199464 DOI: 10.1186/s12957-020-01830-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
162 Douridas GN, Fountoulakis A, Souglakos J, Gourtsoyianni S, Vini L, Levidou G, Liakakos T, Agalianos C, Dervenis C, Kalogeridi MA, Karavokyros I, Koumarianou A, Kountourakis P, Oikonomopoulos G, Economopoulou P, Sgouros J, Sgouros SN, Stamou K, Triantopoulou C, Zacharoulis D, Gouvas N, Xynos E. Consensus statement of the Hellenic and Cypriot Gastric Cancer Study Group on the diagnosis, staging and management of gastric cancer. Updates Surg 2020;72:1-19. [PMID: 32112342 DOI: 10.1007/s13304-020-00723-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 Molina JC, Al-Hinai A, Gosseling-Tardif A, Bouchard P, Spicer J, Mulder D, Mueller CL, Ferri LE. Multivisceral Resection for Locally Advanced Gastric and Gastroesophageal Junction Cancers-11-Year Experience at a High-Volume North American Center. J Gastrointest Surg. 2019;23:43-50. [PMID: 29663302 DOI: 10.1007/s11605-018-3746-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
164 Kim IH. Current status of adjuvant chemotherapy for gastric cancer. World J Gastrointest Oncol 2019;11:679-85. [PMID: 31558973 DOI: 10.4251/wjgo.v11.i9.679] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
165 Schirren R, Novotny A, Slotta-Huspenina J, Friess H, Reim D. Novel Histologic Categorization Based on Lauren Histotypes Conveys Prognostic Information for Gastroesophageal Junction Cancers-Analysis from a Large Single Center Cohort in Germany. Cancers (Basel) 2021;13:1303. [PMID: 33804009 DOI: 10.3390/cancers13061303] [Reference Citation Analysis]
166 Thies S, Langer R. Tumor regression grading of gastrointestinal carcinomas after neoadjuvant treatment. Front Oncol. 2013;3:262. [PMID: 24109590 DOI: 10.3389/fonc.2013.00262] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 8.8] [Reference Citation Analysis]
167 Shin J, Lim JS, Huh YM, Kim JH, Hyung WJ, Chung JJ, Han K, Kim S. A radiomics-based model for predicting prognosis of locally advanced gastric cancer in the preoperative setting. Sci Rep 2021;11:1879. [PMID: 33479398 DOI: 10.1038/s41598-021-81408-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
168 Kashfi SM, Behboudi Farahbakhsh F, Nazemalhosseini Mojarad E, Mashayekhi K, Azimzadeh P, Romani S, Derakhshani S, Malekpour H, Asadzadeh Aghdaei H, Zali MR. Interleukin-16 polymorphisms as new promising biomarkers for risk of gastric cancer. Tumour Biol 2016;37:2119-26. [PMID: 26346169 DOI: 10.1007/s13277-015-4013-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
169 Alderson D, Cunningham D, Nankivell M, Blazeby JM, Griffin SM, Crellin A, Grabsch HI, Langer R, Pritchard S, Okines A, Krysztopik R, Coxon F, Thompson J, Falk S, Robb C, Stenning S, Langley RE. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet Oncol. 2017;18:1249-1260. [PMID: 28784312 DOI: 10.1016/s1470-2045(17)30447-3] [Cited by in Crossref: 100] [Cited by in F6Publishing: 44] [Article Influence: 25.0] [Reference Citation Analysis]
170 Ekheden I, Ebrahim F, Ólafsdóttir H, Raaschou P, Wettermark B, Henriksson R, Ye W. Survival of esophageal and gastric cancer patients with adjuvant and palliative chemotherapy-a retrospective analysis of a register-based patient cohort. Eur J Clin Pharmacol 2020;76:1029-41. [PMID: 32372150 DOI: 10.1007/s00228-020-02883-3] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
171 Glehen O, Passot G, Villeneuve L, Vaudoyer D, Bin-Dorel S, Boschetti G, Piaton E, Garofalo A. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: A randomized and multicenter phase III study. BMC Cancer. 2014;14:183. [PMID: 24628950 DOI: 10.1186/1471-2407-14-183] [Cited by in Crossref: 95] [Cited by in F6Publishing: 64] [Article Influence: 13.6] [Reference Citation Analysis]
172 Yamaoka Y, Fujitani K, Tsujinaka T, Yamamoto K, Hirao M, Sekimoto M. Skeletal muscle loss after total gastrectomy, exacerbated by adjuvant chemotherapy. Gastric Cancer. 2015;18:382-389. [PMID: 24715254 DOI: 10.1007/s10120-014-0365-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
173 Berlth F, Hoelscher AH. History of Esophagogastric Junction Cancer Treatment and Current Surgical Management in Western Countries. J Gastric Cancer 2019;19:139-47. [PMID: 31245158 DOI: 10.5230/jgc.2019.19.e18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
174 Kim S, Fiteni F, Paget-Bailly S, Ghiringhelli F, Lakkis Z, Jary M, Fein F, Bonnetain F, Mariette C, Borg C. The impact of taxane-based preoperative chemotherapy in gastroesophageal signet ring cell adenocarcinomas. J Hematol Oncol. 2015;8:52. [PMID: 25976888 DOI: 10.1186/s13045-015-0148-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
175 Mao C, Zeng X, Zhang C, Yang Y, Xiao X, Luan S, Zhang Y, Yuan Y. Mechanisms of Pharmaceutical Therapy and Drug Resistance in Esophageal Cancer. Front Cell Dev Biol 2021;9:612451. [PMID: 33644048 DOI: 10.3389/fcell.2021.612451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
176 Zhou X, Zhu W, Li H, Wen W, Cheng W, Wang F, Wu Y, Qi L, Fan Y, Chen Y, Ding Y, Xu J, Qian J, Huang Z, Wang T, Zhu D, Shu Y, Liu P. Diagnostic value of a plasma microRNA signature in gastric cancer: a microRNA expression analysis. Sci Rep. 2015;5:11251. [PMID: 26059512 DOI: 10.1038/srep11251] [Cited by in Crossref: 90] [Cited by in F6Publishing: 85] [Article Influence: 15.0] [Reference Citation Analysis]
177 Turgeman I, Ben-Aharon I. Evolving treatment paradigms in esophageal cancer. Ann Transl Med 2021;9:903. [PMID: 34164537 DOI: 10.21037/atm.2020.03.110] [Reference Citation Analysis]
178 Luu C, Thapa R, Woo K, Coppola D, Almhanna K, Pimiento JM, Chen DT, Marquez DD, Hodul PJ. Does histology really influence gastric cancer prognosis? J Gastrointest Oncol 2017;8:1026-36. [PMID: 29299363 DOI: 10.21037/jgo.2017.09.08] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
179 Meyer HJ, Hölscher AH, Lordick F, Messmann H, Mönig S, Schumacher C, Stahl M, Wilke H, Möhler M. [Current S3 guidelines on surgical treatment of gastric carcinoma]. Chirurg 2012;83:31-7. [PMID: 22127381 DOI: 10.1007/s00104-011-2149-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
180 Xie JW, Lu J, Xu BB, Zheng CH, Li P, Wang JB, Lin JX, Chen QY, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Truty MJ, Huang CM. Prognostic Value of Tumor Regression Grading in Patients Treated With Neoadjuvant Chemotherapy Plus Surgery for Gastric Cancer. Front Oncol 2021;11:587856. [PMID: 34386413 DOI: 10.3389/fonc.2021.587856] [Reference Citation Analysis]
181 Liu D, Lu M, Li J, Yang Z, Feng Q, Zhou M, Zhang Z, Shen L. The patterns and timing of recurrence after curative resection for gastric cancer in China. World J Surg Oncol. 2016;14:305. [PMID: 27931221 DOI: 10.1186/s12957-016-1042-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
182 Beeharry MK, Zhang TQ, Liu WT, Gang ZZ. Optimization of perioperative approaches for advanced and late stages of gastric cancer: clinical proposal based on literature evidence, personal experience, and ongoing trials and research. World J Surg Oncol 2020;18:51. [PMID: 32151257 DOI: 10.1186/s12957-020-01819-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
183 Wang ZL, Zhou ZG, Chen Y, Li XT, Sun YS. Support Vector Machines Model of Computed Tomography for Assessing Lymph Node Metastasis in Esophageal Cancer with Neoadjuvant Chemotherapy. J Comput Assist Tomogr. 2017;41:455-460. [PMID: 27879527 DOI: 10.1097/rct.0000000000000555] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
184 Gabriel E, Attwood K, Du W, Tuttle R, Alnaji RM, Nurkin S, Malhotra U, Hochwald SN, Kukar M. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation. JAMA Surg 2016;151:234-45. [PMID: 26559488 DOI: 10.1001/jamasurg.2015.4068] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
185 Moorcraft SY, Smyth EC, Cunningham D. Adjuvant or neoadjuvant therapy for operable esophagogastric cancer? Gastric Cancer 2015;18:1-10. [PMID: 24638977 DOI: 10.1007/s10120-014-0356-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
186 Cananzi FC, Biondi A, Cozzaglio L, D’Ugo D, Persiani R, Quagliuolo V. Preoperative chemotherapy in gastric cancer: expanding the indications, limiting the overuse. Gastric Cancer. 2015;18:200-201. [PMID: 24682591 DOI: 10.1007/s10120-014-0359-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
187 Farrow NE, Freischlag KW, Adam MA, Blazer DG. Impact of minimally invasive gastrectomy on use of and time to adjuvant chemotherapy for gastric adenocarcinoma. J Surg Oncol 2020;121:486-93. [PMID: 31919862 DOI: 10.1002/jso.25834] [Reference Citation Analysis]
188 Peixoto RD, Rocha-Filho DR, Weschenfelder RF, Rego JFM, Riechelmann R, Coutinho AK, Fernandes GS, Jacome AA, Andrade AC, Murad AM, Mello CAL, Miguel DSCG, Gomes DBD, Racy DJ, Moraes ED, Akaishi EH, Carvalho ES, Mello ES, Filho FM, Coimbra FJF, Capareli FC, Arruda FF, Vieira FMAC, Takeda FR, Cotti GCC, Pereira GLS, Paulo GA, Ribeiro HSC, Lourenco LG, Crosara M, Toneto MG, Oliveira MB, de Lourdes Oliveira M, Begnami MD, Forones NM, Yagi O, Ashton-Prolla P, Aguillar PB, Amaral PCG, Hoff PM, Araujo RLC, Filho RPDP, Gansl RC, Gil RA, Pfiffer TEF, Souza T, Jr UR, Jesus VHF, Jr WLC, Prolla G. Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of gastric cancer. Ecancermedicalscience 2020;14:1126. [PMID: 33209117 DOI: 10.3332/ecancer.2020.1126] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
189 Merrett ND. Multimodality treatment of potentially curative gastric cancer: geographical variations and future prospects. World J Gastroenterol. 2014;20:12892-12899. [PMID: 25278686 DOI: 10.3748/wjg.v20.i36.12892] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
190 Goetze TO, Al-Batran SE, Berlth F, Hoelscher AH. Multimodal Treatment Strategies in Esophagogastric Junction Cancer: a Western Perspective. J Gastric Cancer 2019;19:148-56. [PMID: 31245159 DOI: 10.5230/jgc.2019.19.e19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
191 Fujitani K, Kurokawa Y, Takeno A, Endoh S, Ohmori T, Fujita J, Yamasaki M, Takiguchi S, Mori M, Doki Y; Osaka University Clinical Research Group for Gastroenterological Surgery. Time to initiation or duration of S-1 adjuvant chemotherapy; which really impacts on survival in stage II and III gastric cancer? Gastric Cancer 2018;21:446-52. [PMID: 28965205 DOI: 10.1007/s10120-017-0767-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
192 Blank S, Stange A, Sisic L, Roth W, Grenacher L, Sterzing F, Burian M, Jäger D, Büchler M, Ott K. Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients. Langenbecks Arch Surg 2013;398:211-20. [PMID: 23224565 DOI: 10.1007/s00423-012-1034-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
193 Xu AM, Huang L, Liu W, Gao S, Han WX, Wei ZJ. Neoadjuvant chemotherapy followed by surgery versus surgery alone for gastric carcinoma: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9:e86941. [PMID: 24497999 DOI: 10.1371/journal.pone.0086941.ecollection] [Reference Citation Analysis]
194 Khan M, Urooj N, Syed AA, Khattak S, Kazmi A, Ashraf MI, Batool S. Prognostic Factors for Recurrence in Esophageal Cancer Patients Treated With Neoadjuvant Therapy and Surgery: A Single-institution Analysis. Cureus 2020;12:e8108. [PMID: 32542161 DOI: 10.7759/cureus.8108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
195 Özer İ, Bostancı EB, Ulaş M, Özoğul Y, Akoğlu M. Changing Trends in Gastric Cancer Surgery. Balkan Med J 2017;34:10-20. [PMID: 28251018 DOI: 10.4274/balkanmedj.2015.1461] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
196 Park SC, Chun HJ. Chemotherapy for advanced gastric cancer: review and update of current practices. Gut Liver. 2013;7:385-393. [PMID: 23898376 DOI: 10.5009/gnl.2013.7.4.385] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
197 Shao Y, Chen D, Ye L, Wang XM, Wu QC, Zhang C. Survival benefit of perioperative chemotherapy for T1-3N0M0 stage esophageal cancer: a SEER database analysis. J Thorac Dis 2021;13:995-1004. [PMID: 33717572 DOI: 10.21037/jtd-20-2877] [Reference Citation Analysis]
198 Delaunoit T. Latest developments and emerging treatment options in the management of stomach cancer. Cancer Manag Res 2011;3:257-66. [PMID: 21792334 DOI: 10.2147/CMR.S12713] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 0.1] [Reference Citation Analysis]
199 Harada K, Lopez A, Shanbhag N, Badgwell B, Baba H, Ajani J. Recent advances in the management of gastric adenocarcinoma patients. F1000Res 2018;7:F1000 Faculty Rev-1365. [PMID: 30228868 DOI: 10.12688/f1000research.15133.1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
200 Geng X, Zhang X, Zhou B, Zhang C, Tu J, Chen X, Wang J, Gao H, Qin G, Pan W. Usnic Acid Induces Cycle Arrest, Apoptosis, and Autophagy in Gastric Cancer Cells In Vitro and In Vivo. Med Sci Monit 2018;24:556-66. [PMID: 29374767 DOI: 10.12659/msm.908568] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 7.7] [Reference Citation Analysis]
201 Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res 2018;10:239-48. [PMID: 29445300 DOI: 10.2147/CMAR.S149619] [Cited by in Crossref: 339] [Cited by in F6Publishing: 181] [Article Influence: 113.0] [Reference Citation Analysis]
202 Boda-Heggemann J, Weiss C, Schneider V, Hofheinz RD, Haneder S, Michaely H, Wertz H, Ronellenfitsch U, Hochhaus A, Wenz F, Lohr F. Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer. Strahlenther Onkol 2013;189:417-23. [PMID: 23558673 DOI: 10.1007/s00066-013-0309-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
203 Schulze B, Bergis D, Balermpas P, Trojan J, Woeste G, Bechstein WO, Rödel C, Weiss C. Neoadjuvant chemoradiation versus perioperative chemotherapy followed by surgery in resectable adenocarcinomas of the esophagogastric junction: A retrospective single center analysis. Oncol Lett 2014;7:534-40. [PMID: 24396483 DOI: 10.3892/ol.2013.1709] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
204 Wang QW, Zhang XT, Lu M, Shen L. Impact of duration of adjuvant chemotherapy in radically resected patients with T4bN1-3M0/TxN3bM0 gastric cancer. World J Gastrointest Oncol 2018;10:31-9. [PMID: 29375746 DOI: 10.4251/wjgo.v10.i1.31] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
205 Sun J, Wang X, Zhang Z, Zeng Z, Ouyang S, Kang W. The Sensitivity Prediction of Neoadjuvant Chemotherapy for Gastric Cancer. Front Oncol 2021;11:641304. [PMID: 33937042 DOI: 10.3389/fonc.2021.641304] [Reference Citation Analysis]
206 Li K, Chen F, Xie H. Decreased FOXP3+ and GARP+ Tregs to neoadjuvant chemotherapy associated with favorable prognosis in advanced gastric cancer. Onco Targets Ther 2016;9:3525-33. [PMID: 27366089 DOI: 10.2147/OTT.S101884] [Cited by in Crossref: 5] [Article Influence: 1.0] [Reference Citation Analysis]
207 Lordick F, Hölscher AH, Haustermans K, Wittekind C. Multimodal treatment of esophageal cancer. Langenbecks Arch Surg 2013;398:177-87. [PMID: 22971784 DOI: 10.1007/s00423-012-1001-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
208 Goetze OT, Al-Batran SE, Chevallay M, Mönig SP. Multimodal treatment in locally advanced gastric cancer. Updates Surg 2018;70:173-9. [PMID: 29946806 DOI: 10.1007/s13304-018-0539-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
209 Blakely AM, Miner TJ. Surgical considerations in the treatment of gastric cancer. Gastroenterol Clin North Am. 2013;42:337-357. [PMID: 23639644 DOI: 10.1016/j.gtc.2013.01.010.surgical] [Reference Citation Analysis]
210 Yan Y, Yang A, Lu L, Zhao Z, Li C, Li W, Chao J, Liu T, Fong Y, Fu W, Woo Y. Impact of Neoadjuvant Therapy on Minimally Invasive Surgical Outcomes in Advanced Gastric Cancer: An International Propensity Score-Matched Study. Ann Surg Oncol. 2021;28:1428-1436. [PMID: 32862371 DOI: 10.1245/s10434-020-09070-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
211 Xu AM, Huang L, Liu W, Gao S, Han WX, Wei ZJ. Neoadjuvant chemotherapy followed by surgery versus surgery alone for gastric carcinoma: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9:e86941. [PMID: 24497999 DOI: 10.1371/journal.pone.0086941] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 5.6] [Reference Citation Analysis]
212 Costa JM, Gonçalves B, Miguel Gomes M, Fernandes D, Gonçalves R, Soares JB. Accuracy of endoscopic ultrasound in gastric adenocarcinoma patient selection for neoadjuvant therapy. United European Gastroenterol J 2019;7:278-86. [PMID: 31081829 DOI: 10.1177/2050640618818942] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
213 van den Ende T, Ter Veer E, Mali RMA, van Berge Henegouwen MI, Hulshof MCCM, van Oijen MGH, van Laarhoven HWM. Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis. Cancers (Basel) 2019;11:E530. [PMID: 31013858 DOI: 10.3390/cancers11040530] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
214 Langer R, Becker K. Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy. Virchows Arch 2018;472:175-86. [PMID: 28918544 DOI: 10.1007/s00428-017-2232-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
215 Jácome AA, Sankarankutty AK, dos Santos JS. Adjuvant therapy for gastric cancer: what have we learned since INT0116? World J Gastroenterol 2015;21:3850-9. [PMID: 25852269 DOI: 10.3748/wjg.v21.i13.3850] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
216 Seidlitz T, Merker SR, Rothe A, Zakrzewski F, von Neubeck C, Grützmann K, Sommer U, Schweitzer C, Schölch S, Uhlemann H, Gaebler AM, Werner K, Krause M, Baretton GB, Welsch T, Koo BK, Aust DE, Klink B, Weitz J, Stange DE. Human gastric cancer modelling using organoids. Gut 2019;68:207-17. [PMID: 29703791 DOI: 10.1136/gutjnl-2017-314549] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 27.7] [Reference Citation Analysis]
217 Chen W, Yu J, Zhang Y, Wang W, Yu W, Shi X, Xu Z, Liu H. First-line application of apatinib combined with S-1 based on peripheral circulating tumor cell screening to treat advanced gastric adenocarcinoma: a case report. Ann Transl Med 2019;7:181. [PMID: 31168462 DOI: 10.21037/atm.2019.03.68] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
218 Xue K, Ying X, Bu Z, Wu A, Li Z, Tang L, Zhang L, Zhang Y, Li Z, Ji J. Oxaliplatin plus S-1 or capecitabine as neoadjuvant or adjuvant chemotherapy for locally advanced gastric cancer with D2 lymphadenectomy: 5-year follow-up results of a phase II<b>-</b>III randomized trial. Chin J Cancer Res. 2018;30:516-525. [PMID: 30510363 DOI: 10.21147/j.issn.1000-9604.2018.05.05] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
219 Khaled I, Priego P, Soliman H, Faisal M, Saad Ahmed I. Oncological outcomes of laparoscopic versus open gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: a retrospective multicenter study. World J Surg Oncol 2021;19:206. [PMID: 34243773 DOI: 10.1186/s12957-021-02322-2] [Reference Citation Analysis]
220 Kim BJ, Chiang YJ, Das P, Minsky BD, Blum MA, Ajani JA, Estrella JS, Hofstetter WL, Tzeng CD, Badgwell BD, Mansfield PF, Ikoma N. Treatment Patterns for Gastroesophageal Junction Adenocarcinoma in the United States. J Clin Med 2020;9:E3495. [PMID: 33138060 DOI: 10.3390/jcm9113495] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
221 Pelc Z, Skórzewska M, Rawicz-Pruszyński K, Polkowski WP. Lymph Node Involvement in Advanced Gastric Cancer in the Era of Multimodal Treatment-Oncological and Surgical Perspective. Cancers (Basel) 2021;13:2509. [PMID: 34065596 DOI: 10.3390/cancers13102509] [Reference Citation Analysis]
222 Sharfo AWM, Stieler F, Kupfer O, Heijmen BJM, Dirkx MLP, Breedveld S, Wenz F, Lohr F, Boda-Heggemann J, Buergy D. Automated VMAT planning for postoperative adjuvant treatment of advanced gastric cancer. Radiat Oncol 2018;13:74. [PMID: 29685166 DOI: 10.1186/s13014-018-1032-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
223 He Z, Zhao TT, Xu HM, Wang ZN, Xu YY, Song YX, Ni ZR, Xu H, Yin SC, Liu XY, Miao ZF. Efficacy and safety of intraperitoneal chemotherapy in patients with advanced gastric cancer: A cumulative meta-analysis of randomized controlled trials. Oncotarget. 2017;8:81125-81136. [PMID: 29113372 DOI: 10.18632/oncotarget.20818] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
224 Allen S, Brown V, Prabhu P, Scott M, Rockall T, Preston S, Sultan J. A randomised controlled trial to assess whether prehabilitation improves fitness in patients undergoing neoadjuvant treatment prior to oesophagogastric cancer surgery: study protocol. BMJ Open 2018;8:e023190. [PMID: 30580268 DOI: 10.1136/bmjopen-2018-023190] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
225 Li S, Liu H, Diao C, Wang X, Gao M, Li Z, Song L, Gao X, Han J, Wang F, Li W, Han X. Prognosis of surgery combined with different adjuvant therapies in esophageal cancer treatment: a network meta-analysis. Oncotarget 2017;8:36339-53. [PMID: 28423740 DOI: 10.18632/oncotarget.16193] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
226 Voeten DM, van der Werf LR, Wilschut JA, Busweiler LAD, van Sandick JW, van Hillegersberg R, van Berge Henegouwen MI; Dutch Upper Gastrointestinal Cancer Audit Group. Failure to Cure in Patients Undergoing Surgery for Gastric Cancer: A Nationwide Cohort Study. Ann Surg Oncol 2021;28:4484-96. [PMID: 33486644 DOI: 10.1245/s10434-020-09510-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
227 Choi AH, Kim J, Chao J. Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond. World J Gastroenterol. 2015;21:7343-7348. [PMID: 26139980 DOI: 10.3748/wjg.v21.i24.7343] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 37] [Article Influence: 8.6] [Reference Citation Analysis]
228 Nienhüser H, Schmidt T. Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer. Int J Mol Sci 2017;19:E43. [PMID: 29295534 DOI: 10.3390/ijms19010043] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
229 Martin-Romano P, Sola JJ, Diaz-Gonzalez JA, Chopitea A, Iragorri Y, Martínez-Regueira F, Ponz-Sarvise M, Arbea L, Subtil JC, Cano D, Ceniceros L, Legaspi J, Hernandez JL, Rodríguez J. Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer. Br J Cancer 2016;115:655-63. [PMID: 27537382 DOI: 10.1038/bjc.2016.252] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
230 Christina Svensson M, Lindén A, Nygaard J, Borg D, Hedner C, Nodin B, Leandersson K, Jirström K. T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival. Oncoimmunology 2021;10:1921443. [PMID: 34104541 DOI: 10.1080/2162402X.2021.1921443] [Reference Citation Analysis]
231 Mongan AM, Kalachand R, King S, O'Farrell NJ, Power D, Ravi N, Muldoon C, O'Byrne K, Reynolds JV. Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery. Ir J Med Sci. 2015;184:417-423. [PMID: 24879337 DOI: 10.1007/s11845-014-1135-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
232 Goéré D, Gras-Chaput N, Aupérin A, Flament C, Mariette C, Glehen O, Zitvogel L, Elias D. Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab. BMC Cancer 2014;14:148. [PMID: 24589307 DOI: 10.1186/1471-2407-14-148] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
233 Blank S, Knebel P, Haag GM, Bruckner T, Klaiber U, Burian M, Schaible A, Sisic L, Schmidt T, Diener MK, Ott K. Immediate tumor resection in patients with locally advanced gastroesophageal adenocarcinoma with nonresponse to chemotherapy after 4 weeks of treatment versus resection after completion of chemotherapy (OPTITREAT trial, DRKS00004668): study protocol for a randomized controlled pilot trial. Pilot Feasibility Stud 2016;2:18. [PMID: 27965838 DOI: 10.1186/s40814-016-0059-x] [Reference Citation Analysis]
234 Fokas E, Rödel C. Definitive, Preoperative, and Palliative Radiation Therapy of Esophageal Cancer. Viszeralmedizin 2015;31:347-53. [PMID: 26989391 DOI: 10.1159/000440638] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
235 Khalafi S, Lockhart AC, Livingstone AS, El-Rifai W. Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet? Cancers (Basel) 2020;12:E3077. [PMID: 33105560 DOI: 10.3390/cancers12113077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
236 Ohnuma H, Sato Y, Onoyama N, Hamaguchi K, Hayasaka N, Sato M, Murase K, Takada K, Miyanishi K, Murakami T, Ito T, Nobuoka T, Takemasa I, Kato J. Survival benefit of conversion surgery after intensive chemotherapy for unresectable metastatic gastric cancer: a propensity score-matching analysis. J Cancer Res Clin Oncol 2021;147:2385-96. [PMID: 33534051 DOI: 10.1007/s00432-021-03516-7] [Reference Citation Analysis]
237 Aprile G, Leone F, Giampieri R, Casagrande M, Marino D, Faloppi L, Cascinu S, Fasola G, Scartozzi M. Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology. Onco Targets Ther 2015;8:1149-56. [PMID: 26045669 DOI: 10.2147/OTT.S82624] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
238 Soror T, Kho G, Zhao KL, Ismail M, Badakhshi H. Impact of pathological complete response following neoadjuvant chemoradiotherapy in esophageal cancer. J Thorac Dis 2018;10:4069-76. [PMID: 30174850 DOI: 10.21037/jtd.2018.06.85] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
239 Mokadem I, Dijksterhuis WPM, van Putten M, Heuthorst L, de Vos-Geelen JM, Haj Mohammad N, Nieuwenhuijzen GAP, van Laarhoven HWM, Verhoeven RHA. Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study. Gastric Cancer. 2019;. [PMID: 30949777 DOI: 10.1007/s10120-019-00956-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
240 Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: Classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012;3:251-261. [PMID: 22943016 DOI: 10.3978/j.issn.2078-6891.2012.021] [Cited by in F6Publishing: 148] [Reference Citation Analysis]
241 Aoyama T, Yoshikawa T. Adjuvant therapy for locally advanced gastric cancer. Surg Today. 2017;47:1295-1302. [PMID: 28251375 DOI: 10.1007/s00595-017-1493-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
242 Petrillo A, Pompella L, Tirino G, Pappalardo A, Laterza MM, Caterino M, Orditura M, Ciardiello F, Lieto E, Galizia G, Castoro C, De Vita F. Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions. Cancers (Basel) 2019;11:E399. [PMID: 30901943 DOI: 10.3390/cancers11030399] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
243 Huang L, Jansen L, Balavarca Y, Verhoeven RHA, Ruurda JP, Van Eycken L, De Schutter H, Johansson J, Lindblad M, Johannesen TB, Zadnik V, Žagar T, Mägi M, Bastiaannet E, Lagarde SM, van de Velde CJH, Schrotz-King P, Brenner H. Decreasing resection rates for nonmetastatic gastric cancer in Europe and the United States. Clin Transl Med 2020;10:e203. [PMID: 33135354 DOI: 10.1002/ctm2.203] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
244 Ruf C, Thomusch O, Goos M, Makowiec F, Illerhaus G, Ruf G. Impact of neoadjuvant chemotherapy with PELF-protocoll versus surgery alone in the treatment of advanced gastric carcinoma. BMC Surg. 2014;14:5. [PMID: 24461063 DOI: 10.1186/1471-2482-14-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
245 Reynolds JV, Preston SR, O'Neill B, Baeksgaard L, Griffin SM, Mariette C, Cuffe S, Cunningham M, Crosby T, Parker I, Hofland K, Hanna G, Svendsen LB, Donohoe CL, Muldoon C, O'Toole D, Johnson C, Ravi N, Jones G, Corkhill AK, Illsley M, Mellor J, Lee K, Dib M, Marchesin V, Cunnane M, Scott K, Lawner P, Warren S, O'Reilly S, O'Dowd G, Leonard G, Hennessy B, Dermott RM. ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS). BMC Cancer 2017;17:401. [PMID: 28578652 DOI: 10.1186/s12885-017-3386-2] [Cited by in Crossref: 77] [Cited by in F6Publishing: 61] [Article Influence: 19.3] [Reference Citation Analysis]
246 Wang K, Li E, Busuttil RA, Kong JC, Pattison S, Sung JJY, Yu J, El-Omar EM, Simpson JA, Boussioutas A. A cohort study and meta-analysis of the evidence for consideration of Lauren subtype when prescribing adjuvant or palliative chemotherapy for gastric cancer. Ther Adv Med Oncol 2020;12:1758835920930359. [PMID: 32754227 DOI: 10.1177/1758835920930359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
247 Ikoma N, Cormier JN, Feig B, Du XL, Yamal JM, Hofstetter W, Das P, Ajani JA, Roland CL, Fournier K. Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National Cancer Data Base, 2006-2014. Cancer. 2018;124:998-1007. [PMID: 29393964 DOI: 10.1002/cncr.31155] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
248 Andreollo NA, Drizlionoks E, Tercioti-Junior V, Coelho-Neto JS, Ferrer JAP, Carvalheira JBC, Lopes LR. ADJUVANT CHEMORADIOTHERAPY AFTER SUBTOTAL OR TOTAL GASTRECTOMY AND D2 LIMPHADENECTOMY INCREASES SURVIVAL IN ADVANCED GASTRIC CANCER? Arq Bras Cir Dig 2019;32:e1464. [PMID: 31859917 DOI: 10.1590/0102-672020190001e1464] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
249 Wang J, Yang M, Wang Q, Ji G. Comparison of Early Oral Feeding With Traditional Oral Feeding After Total Gastrectomy for Gastric Cancer: A Propensity Score Matching Analysis. Front Oncol 2019;9:1194. [PMID: 31788451 DOI: 10.3389/fonc.2019.01194] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
250 Oh DY, Bang YJ. Adjuvant and neoadjuvant therapy for gastric cancer. Curr Treat Options Oncol. 2013;14:311-320. [PMID: 23686725 DOI: 10.1007/s11864-013-0238-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
251 Xie X, Huang N, Zhang Y, Wei X, Gao M, Li M, Ning J, Liu W, Zhao Q, Wang H, Gu K. MiR-192-5p reverses cisplatin resistance by targeting ERCC3 and ERCC4 in SGC7901/DDP cells. J Cancer 2019;10:1039-51. [PMID: 30854110 DOI: 10.7150/jca.25814] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
252 Batool S, Khan M, Akbar SA, Ashraf I. Risk factors and patterns of recurrence after curative resection in Gastroesophageal Junction Adenocarcinoma. Pak J Med Sci 2019;35:1276-83. [PMID: 31488992 DOI: 10.12669/pjms.35.5.963] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
253 Zhao JH, Gao P, Song YX, Sun JX, Chen XW, Ma B, Yang YC, Wang ZN. Which is better for gastric cancer patients, perioperative or adjuvant chemotherapy: a meta-analysis. BMC Cancer 2016;16:631. [PMID: 27519527 DOI: 10.1186/s12885-016-2667-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
254 Blumenthaler AN, Newhook TE, Ikoma N, Estrella JS, Blum Murphy M, Das P, Minsky BD, Ajani JA, Mansfield PF, Badgwell BD. Concurrent lymphovascular and perineural invasion after preoperative therapy for gastric adenocarcinoma is associated with decreased survival. J Surg Oncol 2021;123:911-22. [PMID: 33400838 DOI: 10.1002/jso.26367] [Reference Citation Analysis]
255 Ozden S, Ozgen Z, Ozyurt H, Gemici C, Yaprak G, Tepetam H, Mayadagli A. Survival in gastric cancer in relation to postoperative adjuvant therapy and determinants. World J Gastroenterol 2015;21:1222-33. [PMID: 25632196 DOI: 10.3748/wjg.v21.i4.1222] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
256 Cui HB, Ge HE, Bai XY, Zhang W, Zhang YY, Wang J, Li X, Xing LP, Guo SH, Wang ZY. Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer. Exp Ther Med 2014;7:1083-8. [PMID: 24940391 DOI: 10.3892/etm.2014.1599] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
257 Moureau-Zabotto L, Teissier E, Cowen D, Azria D, Ellis S, Resbeut M. Impact of the Siewert Classification on the Outcome of Patients Treated by Preoperative Chemoradiotherapy for a Nonmetastatic Adenocarcinoma of the Oesophagogastric Junction. Gastroenterol Res Pract 2015;2015:404203. [PMID: 26448741 DOI: 10.1155/2015/404203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
258 Schmidt T, Sicic L, Blank S, Becker K, Weichert W, Bruckner T, Parakonthun T, Langer R, Büchler MW, Siewert JR, Lordick F, Ott K. Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas. Br J Cancer 2014;110:1712-20. [PMID: 24569472 DOI: 10.1038/bjc.2014.94] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 9.1] [Reference Citation Analysis]
259 Noordman BJ, Shapiro J, Spaander MC, Krishnadath KK, van Laarhoven HW, van Berge Henegouwen MI, Nieuwenhuijzen GA, van Hillegersberg R, Sosef MN, Steyerberg EW, Wijnhoven BP, van Lanschot JJ; SANO study group. Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol. JMIR Res Protoc 2015;4:e79. [PMID: 26121676 DOI: 10.2196/resprot.4320] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
260 van der Wilk BJ, Eyck BM, Spaander MCW, Valkema R, Lagarde SM, Wijnhoven BPL, van Lanschot JJB. Towards an Organ-Sparing Approach for Locally Advanced Esophageal Cancer. Dig Surg 2019;36:462-9. [PMID: 30227434 DOI: 10.1159/000493435] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
261 Ikoma N, Hofstetter WL, Estrella JS, Das P, Minsky BD, Fournier KF, Mansfield PF, Ajani JA, Badgwell BD. The ypT category does not impact overall survival in node negative gastric cancer. J Surg Oncol 2018;117:1721-8. [PMID: 29949666 DOI: 10.1002/jso.25081] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
262 Cheng J, Cai M, Shuai X, Gao J, Wang G, Tao K. Multimodal treatments for resectable esophagogastric junction cancer: a systematic review and network meta-analysis. Ther Adv Med Oncol 2019;11:1758835919838963. [PMID: 31044021 DOI: 10.1177/1758835919838963] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
263 Proserpio I, Rausei S, Barzaghi S, Frattini F, Galli F, Iovino D, Rovera F, Boni L, Dionigi G, Pinotti G. Multimodal treatment of gastric cancer. World J Gastrointest Surg. 2014;6:55-58. [PMID: 24829622 DOI: 10.4240/wjgs.v6.i4.55] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
264 Ohashi M, Morita S, Fukagawa T, Wada T, Kushima R, Onaya H, Katai H. Evaluation of 64-Channel Contrast-Enhanced Multi-detector Row Computed Tomography for Preoperative N Staging in cT2-4 Gastric Carcinoma. World J Surg. 2016;40:165-171. [PMID: 26552913 DOI: 10.1007/s00268-015-3318-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
265 Stahl KA, Olecki EJ, Dixon ME, Peng JS, Torres MB, Gusani NJ, Shen C. Gastric Cancer Treatments and Survival Trends in the United States. Curr Oncol 2020;28:138-51. [PMID: 33704182 DOI: 10.3390/curroncol28010017] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
266 van den Ende T, Ter Veer E, Machiels M, Mali RMA, Abe Nijenhuis FA, de Waal L, Laarman M, Gisbertz SS, Hulshof MCCM, van Oijen MGH, van Laarhoven HWM. The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis. Cancers (Basel) 2019;11:E80. [PMID: 30641964 DOI: 10.3390/cancers11010080] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
267 De Manzoni G, Marrelli D, Baiocchi GL, Morgagni P, Saragoni L, Degiuli M, Donini A, Fumagalli U, Mazzei MA, Pacelli F, Tomezzoli A, Berselli M, Catalano F, Di Leo A, Framarini M, Giacopuzzi S, Graziosi L, Marchet A, Marini M, Milandri C, Mura G, Orsenigo E, Quagliuolo V, Rausei S, Ricci R, Rosa F, Roviello G, Sansonetti A, Sgroi G, Tiberio GA, Verlato G, Vindigni C, Rosati R, Roviello F. The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015. Gastric Cancer 2017;20:20-30. [PMID: 27255288 DOI: 10.1007/s10120-016-0615-3] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 14.2] [Reference Citation Analysis]
268 Worni M, Martin J, Gloor B, Pietrobon R, D'Amico TA, Akushevich I, Berry MF. Does surgery improve outcomes for esophageal squamous cell carcinoma? An analysis using the surveillance epidemiology and end results registry from 1998 to 2008. J Am Coll Surg 2012;215:643-51. [PMID: 23084493 DOI: 10.1016/j.jamcollsurg.2012.07.006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
269 Ott K, Blank S, Becker K, Langer R, Weichert W, Roth W, Sisic L, Stange A, Jäger D, Büchler M. Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor. Langenbecks Arch Surg. 2013;398:239-249. [PMID: 23269519 DOI: 10.1007/s00423-012-1039-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
270 Nusrath S, Thammineedi SR, Vijaya Narsimha Raju KV, Patnaik SC, Pawar S, Santa A, Rajappa SJ, Mallavarapu KM, Raju K, Murthy S. Short-term Outcomes in Patients with Carcinoma of the Esophagus and Gastroesophageal Junction Receiving Neoadjuvant Chemotherapy or Chemoradiation before Surgery. A Prospective Study. Rambam Maimonides Med J 2019;10. [PMID: 29993360 DOI: 10.5041/RMMJ.10339] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
271 Fontana E, Smyth EC, Cunningham D. Esophagogastric Adenocarcinoma: Is More Chemotherapy Better? Curr Treat Options Oncol 2016;17:21. [PMID: 27032643 DOI: 10.1007/s11864-016-0395-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
272 Reddavid R, Sofia S, Chiaro P, Colli F, Trapani R, Esposito L, Solej M, Degiuli M. Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake? World J Gastroenterol. 2018;24:274-289. [PMID: 29375213 DOI: 10.3748/wjg.v24.i2.274] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 24] [Article Influence: 10.3] [Reference Citation Analysis]
273 Bauer K, Schroeder M, Porzsolt F, Henne-Bruns D. Comparison of international guidelines on the accompanying therapy for advanced gastric cancer: reasons for the differences. J Gastric Cancer. 2015;15:10-18. [PMID: 25861518 DOI: 10.5230/jgc.2015.15.1.10] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
274 Maeda O, Ando Y. Recent progress of chemotherapy and biomarkers for gastroesophageal cancer. World J Gastrointest Oncol 2019;11:518-26. [PMID: 31367271 DOI: 10.4251/wjgo.v11.i7.518] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
275 Zhao J, Wang G, Jiang ZW, Jiang CW, Liu J, Xia CC, Li JS. Patients Administered Neoadjuvant Chemotherapy Could be Enrolled into an Enhanced Recovery after Surgery Program for Locally Advanced Gastric Cancer. Chin Med J (Engl) 2018;131:413-9. [PMID: 29451145 DOI: 10.4103/0366-6999.225047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
276 Shimada H, Fukagawa T, Haga Y, Okazumi SI, Oba K. Clinical TNM staging for esophageal, gastric, and colorectal cancers in the era of neoadjuvant therapy: A systematic review of the literature. Ann Gastroenterol Surg 2021;5:404-18. [PMID: 34337289 DOI: 10.1002/ags3.12444] [Reference Citation Analysis]
277 Elimova E, Shiozaki H, Wadhwa R, Sudo K, Chen Q, Estrella JS, Blum MA, Badgwell B, Das P, Song S, Ajani JA. Medical management of gastric cancer: a 2014 update. World J Gastroenterol 2014;20:13637-47. [PMID: 25320502 DOI: 10.3748/wjg.v20.i38.13637] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
278 Kodera Y. Neoadjuvant chemotherapy for gastric adenocarcinoma in Japan. Surg Today. 2017;47:899-907. [PMID: 28247105 DOI: 10.1007/s00595-017-1473-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
279 Minnella EM, Awasthi R, Loiselle SE, Agnihotram RV, Ferri LE, Carli F. Effect of Exercise and Nutrition Prehabilitation on Functional Capacity in Esophagogastric Cancer Surgery: A Randomized Clinical Trial. JAMA Surg 2018;153:1081-9. [PMID: 30193337 DOI: 10.1001/jamasurg.2018.1645] [Cited by in Crossref: 95] [Cited by in F6Publishing: 77] [Article Influence: 47.5] [Reference Citation Analysis]
280 Liu L, Wang YC, Liu QW, Zhong JD, Li JB, Wu XD, Qin HY. Home enteral nutrition after esophagectomy for esophageal cancer: A systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e21988. [PMID: 32899043 DOI: 10.1097/MD.0000000000021988] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
281 Shridhar R, Imani-Shikhabadi R, Davis B, Streeter OA, Thomas CR Jr. Curative treatment of esophageal cancer; an evidenced based review. J Gastrointest Cancer 2013;44:375-84. [PMID: 23824628 DOI: 10.1007/s12029-013-9511-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
282 MacGregor TP, Carter R, Gillies RS, Findlay JM, Kartsonaki C, Castro-Giner F, Sahgal N, Wang LM, Chetty R, Maynard ND, Cazier JB, Buffa F, McHugh PJ, Tomlinson I, Middleton MR, Sharma RA. Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma. Sci Rep 2018;8:7265. [PMID: 29739952 DOI: 10.1038/s41598-018-24232-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
283 Klevebro F, Tsekrekos A, Low D, Lundell L, Vieth M, Detlefsen S. Relevant issues in tumor regression grading of histopathological response to neoadjuvant treatment in adenocarcinomas of the esophagus and gastroesophageal junction. Dis Esophagus 2020;33:doaa005. [PMID: 32141500 DOI: 10.1093/dote/doaa005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
284 Martin-Richard M, Custodio A, García-Girón C, Grávalos C, Gomez C, Jimenez-Fonseca P, Manzano JL, Pericay C, Rivera F, Carrato A. Seom guidelines for the treatment of gastric cancer 2015. Clin Transl Oncol 2015;17:996-1004. [PMID: 26691658 DOI: 10.1007/s12094-015-1456-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
285 Ji X, Yang Q, Qin H, Zhou J, Liu W. Tumor blood supply may predict neoadjuvant chemotherapy response and survival in patients with gastric cancer. J Int Med Res. 2019;47:2524-2532. [PMID: 31039658 DOI: 10.1177/0300060519845491] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
286 Zhou Y, Tian M, Güngör C, Wang D. Neoadjuvant radiotherapy for locoregional Siewert type II gastroesophageal junction adenocarcinoma: A propensity scores matching analysis. PLoS One 2021;16:e0251555. [PMID: 33979405 DOI: 10.1371/journal.pone.0251555] [Reference Citation Analysis]
287 Stark AP, Blum MM, Chiang YJ, Das P, Minsky BD, Estrella JS, Ajani JA, Badgwell BD, Mansfield P, Ikoma N. Preoperative Therapy Regimen Influences the Incidence and Implication of Nodal Downstaging in Patients with Gastric Cancer. J Gastric Cancer 2020;20:313-27. [PMID: 33024587 DOI: 10.5230/jgc.2020.20.e29] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
288 Seidlitz T, Chen YT, Uhlemann H, Schölch S, Kochall S, Merker SR, Klimova A, Hennig A, Schweitzer C, Pape K, Baretton GB, Welsch T, Aust DE, Weitz J, Koo BK, Stange DE. Mouse Models of Human Gastric Cancer Subtypes With Stomach-Specific CreERT2-Mediated Pathway Alterations. Gastroenterology 2019;157:1599-1614.e2. [PMID: 31585123 DOI: 10.1053/j.gastro.2019.09.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
289 Villanueva L, Anabalon J, Butte JM, Salman P, Panay S, Milla E, Gallardo C, Hoefler S, Charles R, Reyes F, Barajas O, Matamala L, Molina A, Portiño S, Berrios M, Caglevic C, Mahave M. Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety. Ecancermedicalscience 2021;15:1168. [PMID: 33680082 DOI: 10.3332/ecancer.2021.1168] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
290 Zhang X, Huang H, Wei Z, Zhu Z, Yang D, Fu H, Xu J, Hu Z, Zhang Y, You Q, Huang X, Yan R, Wang W, Cai Q. Comparison of Docetaxel + Oxaliplatin + S-1 vs Oxalipatin + S-1 as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis. Cancer Manag Res 2020;12:6641-53. [PMID: 32801898 DOI: 10.2147/CMAR.S258360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
291 Kung CH, Tsai JA, Lundell L, Johansson J, Nilsson M, Lindblad M. Nationwide study of the impact of D2 lymphadenectomy on survival after gastric cancer surgery. BJS Open 2020;4:424-31. [PMID: 32129948 DOI: 10.1002/bjs5.50270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
292 Li J. Gastric Cancer in Young Adults: A Different Clinical Entity from Carcinogenesis to Prognosis. Gastroenterol Res Pract 2020;2020:9512707. [PMID: 32190044 DOI: 10.1155/2020/9512707] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
293 Hölscher AH, Fetzner UK. [Modern diagnostics and stage-oriented surgery: therapy of adenocarcinoma of the esophagogastric junction]. Chirurg 2012;83:702-8, 710-1. [PMID: 22878576 DOI: 10.1007/s00104-011-2264-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
294 Li Z, Zhang D, Dai Y, Dong J, Wu L, Li Y, Cheng Z, Ding Y, Liu Z. Computed tomography-based radiomics for prediction of neoadjuvant chemotherapy outcomes in locally advanced gastric cancer: A pilot study. Chin J Cancer Res. 2018;30:406-414. [PMID: 30210220 DOI: 10.21147/j.issn.1000-9604.2018.04.03] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
295 Ludwig K, Möller D, Bernhardt J. [Surgical management for early stage gastric cancer]. Chirurg 2018;89:347-57. [PMID: 29075796 DOI: 10.1007/s00104-017-0541-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
296 Orditura M, Galizia G, Di Martino N, Ancona E, Castoro C, Pacelli R, Morgillo F, Rossetti S, Gambardella V, Farella A. Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma-a pilot study. Curr Oncol. 2014;21:125-133. [PMID: 24940093 DOI: 10.3747/co.21.1570] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
297 Li Z, Shan F, Wang Y, Zhang Y, Zhang L, Li S, Jia Y, Xue K, Miao R, Li Z, Ji J. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis. PLoS One 2018;13:e0189294. [PMID: 29370182 DOI: 10.1371/journal.pone.0189294] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
298 Voron T, Messager M, Duhamel A, Lefevre J, Mabrut JY, Goere D, Meunier B, Brigand C, Hamy A, Glehen O, Mariette C, Paye F. Is signet-ring cell carcinoma a specific entity among gastric cancers? Gastric Cancer. 2016;19:1027-1040. [PMID: 26606931 DOI: 10.1007/s10120-015-0564-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 4.2] [Reference Citation Analysis]
299 Batista TP, Martins MR. Lymph node dissection for gastric cancer: a critical review. Oncol Rev 2012;6:e12. [PMID: 25992202 DOI: 10.4081/oncol.2012.e12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
300 Fujishima H, Fumoto S, Shibata T, Nishiki K, Tsukamoto Y, Etoh T, Moriyama M, Shiraishi N, Inomata M. A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer. PLoS One 2017;12:e0188098. [PMID: 29136005 DOI: 10.1371/journal.pone.0188098] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
301 Wu L, Ge L, Qin Y, Huang M, Chen J, Yang Y, Zhong J. Postoperative morbidity and mortality after neoadjuvant chemotherapy vs upfront surgery for locally advanced gastric cancer: a propensity score matching analysis. Cancer Manag Res. 2019;11:6011-6018. [PMID: 31308742 DOI: 10.2147/cmar.s203880] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
302 Biebl M, Andreou A, Chopra S, Denecke C, Pratschke J. Upper Gastrointestinal Surgery: Robotic Surgery versus Laparoscopic Procedures for Esophageal Malignancy. Visc Med 2018;34:10-5. [PMID: 29594164 DOI: 10.1159/000487011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
303 Rucker AJ, Raman V, Jawitz OK, Voigt SL, Harpole DH, D'Amico TA, Tong BC. The Impact of Adjuvant Therapy on Survival After Esophagectomy for Node-negative Esophageal Adenocarcinoma. Ann Surg 2020. [PMID: 32209899 DOI: 10.1097/SLA.0000000000003886] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
304 Liu Z, Wang Y, Shan F, Ying X, Zhang Y, Li S, Jia Y, Miao R, Xue K, Li Z, Li Z, Ji J. Treatment Switch in Poor Responders with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy. Ann Surg Oncol 2021. [PMID: 34327603 DOI: 10.1245/s10434-021-10087-x] [Reference Citation Analysis]
305 Yu Z, Guo X, Jiang Y, Teng L, Luo J, Wang P, Liang Y, Zhang H. Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive: a systemic review and network meta-analysis. Breast Cancer 2018;25:8-16. [PMID: 28755088 DOI: 10.1007/s12282-017-0794-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
306 Piessen G, Messager M, Le Malicot K, Robb WB, Di Fiore F, Guilbert M, Moreau M, Christophe V, Adenis A, Mariette C. Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas - PRODIGE 19 - FFCD1103 - ADCI002. BMC Cancer. 2013;13:281. [PMID: 23758655 DOI: 10.1186/1471-2407-13-281] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
307 Cheng X, Fan K, Wang L, Ying X, Sanders AJ, Guo T, Xing X, Zhou M, Du H, Hu Y, Ding H, Li Z, Wen X, Jiang W, Yan X, Ji J. TfR1 binding with H-ferritin nanocarrier achieves prognostic diagnosis and enhances the therapeutic efficacy in clinical gastric cancer. Cell Death Dis 2020;11:92. [PMID: 32024821 DOI: 10.1038/s41419-020-2272-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
308 van den Ende T, Abe Nijenhuis FA, van den Boorn HG, Ter Veer E, Hulshof MCCM, Gisbertz SS, van Oijen MGH, van Laarhoven HWM. COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis. Front Oncol 2019;9:684. [PMID: 31403035 DOI: 10.3389/fonc.2019.00684] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
309 Gao X, Zhang Y, Yuan F, Ding B, Ma Q, Yang W, Yan J, Du L, Wang B, Yan F, Sedlmair M, Pan Z, Zhang H. Locally advanced gastric cancer: total iodine uptake to predict the response of primary lesion to neoadjuvant chemotherapy. J Cancer Res Clin Oncol. 2018;144:2207-2218. [PMID: 30094537 DOI: 10.1007/s00432-018-2728-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
310 Voeten DM, Elfrink AKE, Gisbertz SS, Ruurda JP, van Hillegersberg R, van Berge Henegouwen MI. Minimally Invasive Oncologic Upper Gastrointestinal Surgery can be Performed Safely on all Weekdays: A Nationwide Cohort Study. World J Surg 2021;45:2816-29. [PMID: 34032925 DOI: 10.1007/s00268-021-06160-x] [Reference Citation Analysis]
311 Gabrielson S, Tsai JA, Celebioglu F, Nilsson M, Rouvelas I, Lindblad M, Bjäreback A, Tomson A, Axelsson R. "Sentinel lymph node imaging with sequential SPECT/CT lymphoscintigraphy before and after neoadjuvant chemoradiotherapy in patients with cancer of the oesophagus or gastro-oesophageal junction - a pilot study". Cancer Imaging 2018;18:53. [PMID: 30563571 DOI: 10.1186/s40644-018-0185-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
312 Lavery A, Turkington RC. Transcriptomic biomarkers for predicting response to neoadjuvant treatment in oesophageal cancer. Gastroenterol Rep (Oxf) 2020;8:411-24. [PMID: 33442473 DOI: 10.1093/gastro/goaa065] [Reference Citation Analysis]
313 Mizrak Kaya D, Harada K, Amlashi FG, Vasilakopoulou M, Ajani JA. Customization of therapy for gastroesophageal adenocarcinoma patients. Chronic Dis Transl Med 2018;4:8-17. [PMID: 29756119 DOI: 10.1016/j.cdtm.2018.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
314 Kim HS, Kim JH, Kim JW, Kim BC. Chemotherapy in Elderly Patients with Gastric Cancer. J Cancer 2016;7:88-94. [PMID: 26722364 DOI: 10.7150/jca.13248] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
315 Smyth EC, Cunningham D. Operable gastro-oesophageal junctional adenocarcinoma: Where to next? World J Gastrointest Oncol 2014;6:145-55. [PMID: 24936225 DOI: 10.4251/wjgo.v6.i6.145] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
316 Thomas A, Virdee PS, Eatock M, Lord SR, Falk S, Anthoney DA, Turkington RC, Goff M, Elhussein L, Collins L, Love S, Moschandreas J, Middleton MR. Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma. Eur J Cancer 2020;124:131-41. [PMID: 31765988 DOI: 10.1016/j.ejca.2019.10.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
317 Ypsilantis PP, Siddique M, Sohn HM, Davies A, Cook G, Goh V, Montana G. Predicting Response to Neoadjuvant Chemotherapy with PET Imaging Using Convolutional Neural Networks. PLoS One. 2015;10:e0137036. [PMID: 26355298 DOI: 10.1371/journal.pone.0137036] [Cited by in Crossref: 88] [Cited by in F6Publishing: 79] [Article Influence: 14.7] [Reference Citation Analysis]
318 Jeromen A, Oblak I, Anderluh F, Velenik V, Vidmar MS, Ratoša I. Results of postoperative radiochemotherapy of the patients with resectable gastroesophageal junction adenocarcinoma in Slovenia. Radiol Oncol 2012;46:337-45. [PMID: 23412351 DOI: 10.2478/v10019-012-0049-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
319 Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, Lagergren P, Cunningham D. Oesophageal cancer. Nat Rev Dis Primers. 2017;3:17048. [PMID: 28748917 DOI: 10.1038/nrdp.2017.48] [Cited by in Crossref: 249] [Cited by in F6Publishing: 215] [Article Influence: 62.3] [Reference Citation Analysis]
320 Wang SC, Chou JF, Strong VE, Brennan MF, Capanu M, Coit DG. Pretreatment Neutrophil to Lymphocyte Ratio Independently Predicts Disease-specific Survival in Resectable Gastroesophageal Junction and Gastric Adenocarcinoma. Ann Surg. 2016;263:292-297. [PMID: 25915915 DOI: 10.1097/sla.0000000000001189] [Cited by in Crossref: 81] [Cited by in F6Publishing: 54] [Article Influence: 16.2] [Reference Citation Analysis]
321 Smyth E, Knödler M, Giraut A, Mauer M, Nilsson M, Van Grieken N, Wagner AD, Moehler M, Lordick F. VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study. Front Oncol 2019;9:1320. [PMID: 32083013 DOI: 10.3389/fonc.2019.01320] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 18.0] [Reference Citation Analysis]
322 Cai Z, Yin Y, Zhao Z, Xin C, Cai Z, Yin Y, Shen C, Yin X, Wang J, Chen Z, Zhou Y, Zhang B. Comparative effectiveness of neoadjuvant treatments for resectable gastroesophageal cancer: a network meta-analysis. Front Pharmacol. 2018;9:872. [PMID: 30127746 DOI: 10.3389/fphar.2018.00872] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
323 Rau B, Brandl A, Thuss-Patience P, Bergner F, Raue W, Arnold A, Horst D, Pratschke J, Biebl M. The efficacy of treatment options for patients with gastric cancer and peritoneal metastasis. Gastric Cancer. 2019;22:1226-1237. [PMID: 31065877 DOI: 10.1007/s10120-019-00969-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
324 Matuszcak C, Haier J, Hummel R, Lindner K. MicroRNAs: promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential. World J Gastroenterol 2014;20:13658-66. [PMID: 25320504 DOI: 10.3748/wjg.v20.i38.13658] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
325 Schuhmacher C, Reim D, Novotny A. Neoadjuvant treatment for gastric cancer. J. Gastric Cancer. 2013;13:73-78. [PMID: 23844320 DOI: 10.5230/jgc.2013.13.2.73] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
326 Wang FH, Zhang XT, Li YF, Tang L, Qu XJ, Ying JE, Zhang J, Sun LY, Lin RB, Qiu H, Wang C, Qiu MZ, Cai MY, Wu Q, Liu H, Guan WL, Zhou AP, Zhang YJ, Liu TS, Bi F, Yuan XL, Rao SX, Xin Y, Sheng WQ, Xu HM, Li GX, Ji JF, Zhou ZW, Liang H, Zhang YQ, Jin J, Shen L, Li J, Xu RH. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond) 2021;41:747-95. [PMID: 34197702 DOI: 10.1002/cac2.12193] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
327 Manzini G, Klotz U, Henne-Bruns D, Kremer M. Validity of studies suggesting preoperative chemotherapy for resectable thoracic esophageal cancer: A critical appraisal of randomized trials. World J Gastrointest Oncol. 2020;12:113-123. [PMID: 31966919 DOI: 10.4251/wjgo.v12.i1.113] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
328 Taketa T, Sudo K, Wadhawa R, Blum MM, Ajani JA. Adjuvant therapy in gastric cancer: what is the optimal approach? Curr Oncol Rep. 2013;15:146-151. [PMID: 23355076 DOI: 10.1007/s11912-013-0298-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
329 Li Z, Gao X, Peng X, May Chen MJ, Li Z, Wei B, Wen X, Wei B, Dong Y, Bu Z, Wu A, Wu Q, Tang L, Li Z, Liu Y, Zhang L, Jia S, Zhang L, Shan F, Zhang J, Wu X, Ji X, Ji K, Wu X, Shi J, Xing X, Wu J, Lv G, Shen L, Ji X, Liang H, Ji J. Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy. Sci Adv 2020;6:eaay4211. [PMID: 32133402 DOI: 10.1126/sciadv.aay4211] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 14.0] [Reference Citation Analysis]
330 Barzi A, Yang D, Kim AW, Shah MA, Sadeghi S. Comparative effectiveness of treatment modalities in non-metastatic gastric adenocarcinoma: a propensity score matching analysis of the National Cancer Database. BMJ Open Gastroenterol 2020;7:e000483. [PMID: 33148789 DOI: 10.1136/bmjgast-2020-000483] [Reference Citation Analysis]
331 Blank S, Lordick F, Bader F, Burian M, Dobritz M, Grenacher L, Becker K, Weichert W, Langer R, Sisic L, Stange A, Jäger D, Büchler M, Bruckner T, Siewert J, Ott K. Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation. Gastric Cancer 2015;18:314-25. [PMID: 24722800 DOI: 10.1007/s10120-014-0367-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
332 Zhu X, Ko YJ, Berry S, Shah K, Lee E, Chan K. A Bayesian network meta-analysis on second-line systemic therapy in advanced gastric cancer. Gastric Cancer 2017;20:646-54. [PMID: 27722826 DOI: 10.1007/s10120-016-0656-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
333 Chuang J, Gong J, Klempner SJ, Woo Y, Chao J. Refining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classification. J Gastrointest Oncol 2018;9:560-72. [PMID: 29998022 DOI: 10.21037/jgo.2018.03.01] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
334 Tran P, Nguyen C, Klempner SJ. Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes? Int Neurourol J 2016;20:S131-140. [PMID: 27915478 DOI: 10.5213/inj.1632740.370] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
335 Raigani S, Hardacre JM, Kim J, Ammori JB. Trends in the surgical treatment of gastric adenocarcinoma. Ann Surg Oncol. 2014;21:569-574. [PMID: 24165900 DOI: 10.1245/s10434-013-3314-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
336 Bokemeyer C, Stein A, Ridwelski K, Atanackovic D, Arnold D, Wöll E, Ulrich A, Fischer R, Krüger C, Schuhmacher C. A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer. Gastric Cancer 2015;18:833-42. [PMID: 25214034 DOI: 10.1007/s10120-014-0423-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
337 Wang Y, Lei X, Liu Z, Shan F, Ying X, Li Z, Ji J. Short-term outcomes of laparoscopic versus open total gastrectomy after neoadjuvant chemotherapy: a cohort study using the propensity score matching method. J Gastrointest Oncol 2021;12:237-48. [PMID: 34012622 DOI: 10.21037/jgo-20-374] [Reference Citation Analysis]
338 Garg PK, Sharma J, Jakhetiya A, Goel A, Gaur MK. Preoperative therapy in locally advanced esophageal cancer. World J Gastroenterol. 2016;22:8750-8759. [PMID: 27818590 DOI: 10.3748/wjg.v22.i39.8750] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
339 Wang Y, Cheng X, Cui YH, Hou J, Ji Y, Sun YH, Shen ZB, Liu FL, Liu TS. Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis. BMC Cancer 2018;18:702. [PMID: 29954358 DOI: 10.1186/s12885-018-4615-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
340 Hosoda K, Niihara M, Harada H, Yamashita K, Hiki N. Robot-assisted minimally invasive esophagectomy for esophageal cancer: Meticulous surgery minimizing postoperative complications. Ann Gastroenterol Surg 2020;4:608-17. [PMID: 33319150 DOI: 10.1002/ags3.12390] [Reference Citation Analysis]
341 Kleinberg L, Brock M, Gibson M. Management of Locally Advanced Adenocarcinoma of the Esophagus and Gastroesophageal Junction: Finally a Consensus. Curr Treat Options Oncol 2015;16:35. [PMID: 26112428 DOI: 10.1007/s11864-015-0352-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
342 Bauer K, Manzini G, Henne-Bruns D, Buechler P. Perioperative chemotherapy for advanced gastric cancer - results from a tertiary-care hospital in Germany. World J Gastrointest Oncol 2020;12:559-68. [PMID: 32461787 DOI: 10.4251/wjgo.v12.i5.559] [Reference Citation Analysis]
343 Sun Z, Zhu RJ, Yang GF, Li Y. Neoadjuvant chemotherapy with FOLFOX4 regimen to treat advanced gastric cancer improves survival without increasing adverse events: a retrospective cohort study from a Chinese center. ScientificWorldJournal 2014;2014:418694. [PMID: 25136668 DOI: 10.1155/2014/418694] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
344 Liu T, Ding S, Dang J, Wang H, Chen J, Li G. Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis. Radiat Oncol 2019;14:176. [PMID: 31619265 DOI: 10.1186/s13014-019-1388-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
345 Marrelli D, Polom K, de Manzoni G, Morgagni P, Baiocchi GL, Roviello F. Multimodal treatment of gastric cancer in the west: Where are we going? World J Gastroenterol. 2015;21:7954-7969. [PMID: 26185368 DOI: 10.3748/wjg.v21.i26.7954] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 36] [Article Influence: 7.2] [Reference Citation Analysis]
346 Zhou HY, Zheng SP, Li AL, Gao QL, Ou QY, Chen YJ, Wu ST, Lin DG, Liu SB, Huang LY, Li FS, Zhu HY, Qiao GB, Lanuti M, Yao HR, Yu YF. Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study). EClinicalMedicine 2020;24:100422. [PMID: 32637899 DOI: 10.1016/j.eclinm.2020.100422] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
347 Kim JH, Park SR, Ryu MH, Ryoo BY, Kim KP, Kim BS, Yoo MW, Yook JH, Kim BS, Kim J. Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis. Cancer Res Treat. 2018;50:518-529. [PMID: 28546521 DOI: 10.4143/crt.2017.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
348 Schuhmacher C, Reim D, Novotny A. Neoadjuvant treatment for gastric cancer. J Gastric Cancer. 2013;13:73-78. [PMID: 23844320 DOI: 10.5230/jgc.2013] [Reference Citation Analysis]
349 Schirren R, Novotny A, Friess H, Reim D. Histopathologic Response Is a Positive Predictor of Overall Survival in Patients Undergoing Neoadjuvant/Perioperative Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Cancers-Analysis from a Large Single Center Cohort in Germany. Cancers (Basel) 2020;12:E2244. [PMID: 32796715 DOI: 10.3390/cancers12082244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
350 Ma L, Wang Z, Xie M, Quan Y, Zhu W, Yang F, Zhao C, Fan Y, Fang N, Jiang H, Wang Q, Wang S, Zhou J, Chen X, Shu Y. Silencing of circRACGAP1 sensitizes gastric cancer cells to apatinib via modulating autophagy by targeting miR-3657 and ATG7. Cell Death Dis 2020;11:169. [PMID: 32139670 DOI: 10.1038/s41419-020-2352-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 21.0] [Reference Citation Analysis]
351 Zhao Q, Li Y, Wang J, Zhang J, Qiao X, Tan B, Tian Y, Shi G, Xu Q, Li R, Liu Y, Yang P. Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction. Am J Med Sci 2015;349:472-6. [PMID: 25996101 DOI: 10.1097/MAJ.0000000000000476] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
352 Basso V, Orry D, Fraisse J, Vincent J, Hennequin A, Bengrine L, Ghiringhelli F. Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study. World J Gastrointest Oncol 2019;11:634-41. [PMID: 31435464 DOI: 10.4251/wjgo.v11.i8.634] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
353 Kohlruss M, Ott K, Grosser B, Jesinghaus M, Slotta-Huspenina J, Novotny A, Hapfelmeier A, Schmidt T, Gaida MM, Weichert W, Keller G. Sexual Difference Matters: Females with High Microsatellite Instability Show Increased Survival after Neoadjuvant Chemotherapy in Gastric Cancer. Cancers (Basel) 2021;13:1048. [PMID: 33801374 DOI: 10.3390/cancers13051048] [Reference Citation Analysis]
354 Gubanski M, Glimelius B, Lind PA. Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin). Med Oncol 2014;31:906. [PMID: 24627237 DOI: 10.1007/s12032-014-0906-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
355 Cravo M, Fidalgo C, Garrido R, Rodrigues T, Luz G, Palmela C, Santos M, Lopes F, Maio R. Towards curative therapy in gastric cancer: Faraway, so close! World J Gastroenterol 2015;21:11609-20. [PMID: 26556990 DOI: 10.3748/wjg.v21.i41.11609] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
356 Schirren R, Reim D, Novotny AR. Adjuvant and/or neoadjuvant therapy for gastric cancer? A perspective review. Ther Adv Med Oncol. 2015;7:39-48. [PMID: 25553082 DOI: 10.1177/1758834014558839] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
357 Parisi A, Cortellini A, Roberto M, Venditti O, Santini D, Dell'Aquila E, Stellato M, Marchetti P, Occhipinti MA, Zoratto F, Mazzuca F, Tinari N, De Tursi M, Iezzi L, Natoli C, Ratti M, Pizzo C, Ghidini M, Porzio G, Ficorella C, Cannita K. Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. J Cancer Res Clin Oncol 2019;145:2365-73. [PMID: 31280347 DOI: 10.1007/s00432-019-02971-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
358 Wiedmann MW, Mössner J. New and emerging combination therapies for esophageal cancer. Cancer Manag Res 2013;5:133-46. [PMID: 23869177 DOI: 10.2147/CMAR.S32199] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
359 Ma F, Zhang Y, Peng L, Zhang Z, Yang W, Chai J, Zhang B, Ji S, Hua Y, Chen X, Luo S. Which is the optimal management for locally advanced gastric cancer patients with TRG 0 and 1 after R0 resection? Ann Transl Med 2020;8:948. [PMID: 32953748 DOI: 10.21037/atm-20-3986] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
360 Zhu Z, Gong YB, Xu HM. Neoadjuvant therapy strategies for advanced gastric cancer: Current innovations and future challenges. Chronic Dis Transl Med 2020;6:147-57. [PMID: 32908968 DOI: 10.1016/j.cdtm.2020.03.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
361 Díaz Del Arco C, Ortega Medina L, Estrada Muñoz L, García Gómez de Las Heras S, Fernández Aceñero MJ. Is there still a place for conventional histopathology in the age of molecular medicine? Laurén classification, inflammatory infiltration and other current topics in gastric cancer diagnosis and prognosis. Histol Histopathol 2021;36:587-613. [PMID: 33565601 DOI: 10.14670/HH-18-309] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
362 Stark AP, Estrella JS, Chiang YJ, Das P, Minsky BD, Blum Murphy MA, Ajani JA, Mansfield P, Badgwell BD, Ikoma N. Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer. J Surg Oncol 2020;122:422-32. [PMID: 32462681 DOI: 10.1002/jso.25984] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
363 Blumenthaler AN, Ikoma N, Blum M, Das P, Minsky BD, Mansfield PF, Ajani JA, Badgwell BD. Relationship between initial management strategy and survival in patients with gastric outlet obstruction due to gastric cancer. J Surg Oncol 2020;122:1373-82. [PMID: 32810292 DOI: 10.1002/jso.26177] [Reference Citation Analysis]
364 Marrelli D, Polom K, Neri A, Roviello F. Clinical impact of molecular classifications in gastric cancer. Updates Surg 2018;70:225-32. [PMID: 29796937 DOI: 10.1007/s13304-018-0546-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
365 Borg D, Larsson AH, Hedner C, Nodin B, Johnsson A, Jirström K. Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma. J Transl Med 2018;16:290. [PMID: 30355278 DOI: 10.1186/s12967-018-1668-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
366 Aichler M, Motschmann M, Jütting U, Luber B, Becker K, Ott K, Lordick F, Langer R, Feith M, Siewert JR, Walch A. Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy. Oncotarget 2014;5:6620-32. [PMID: 25216514 DOI: 10.18632/oncotarget.2268] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
367 Lundsgaard Hansen M, Fallentin E, Lauridsen C, Law I, Federspiel B, Bæksgaard L, Svendsen LB, Nielsen MB. Computed tomography (CT) perfusion as an early predictive marker for treatment response to neoadjuvant chemotherapy in gastroesophageal junction cancer and gastric cancer--a prospective study. PLoS One 2014;9:e97605. [PMID: 24845062 DOI: 10.1371/journal.pone.0097605] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
368 Meyer HJ, Wilke H. Treatment strategies in gastric cancer. Dtsch Arztebl Int. 2011;108:698-705; quiz 706. [PMID: 22114638 DOI: 10.3238/arztebl.2011.0698] [Cited by in Crossref: 3] [Cited by in F6Publishing: 29] [Article Influence: 0.3] [Reference Citation Analysis]
369 Wang XZ, Zeng ZY, Ye X, Sun J, Zhang ZM, Kang WM. Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines. World J Gastrointest Oncol. 2020;12:37-53. [PMID: 31966912 DOI: 10.4251/wjgo.v12.i1.37] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
370 Borggreve AS, Goense L, Brenkman HJF, Mook S, Meijer GJ, Wessels FJ, Verheij M, Jansen EPM, van Hillegersberg R, van Rossum PSN, Ruurda JP. Imaging strategies in the management of gastric cancer: current role and future potential of MRI. Br J Radiol 2019;92:20181044. [PMID: 30789792 DOI: 10.1259/bjr.20181044] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
371 Borggreve AS, Mook S, Verheij M, Mul VEM, Bergman JJ, Bartels-Rutten A, Ter Beek LC, Beets-Tan RGH, Bennink RJ, van Berge Henegouwen MI, Brosens LAA, Defize IL, van Dieren JM, Dijkstra H, van Hillegersberg R, Hulshof MC, van Laarhoven HWM, Lam MGEH, van Lier ALHMW, Muijs CT, Nagengast WB, Nederveen AJ, Noordzij W, Plukker JTM, van Rossum PSN, Ruurda JP, van Sandick JW, Weusten BLAM, Voncken FEM, Yakar D, Meijer GJ; PRIDE study group. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study. BMC Cancer 2018;18:1006. [PMID: 30342494 DOI: 10.1186/s12885-018-4892-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
372 Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, Toh Y, Doki Y, Naomoto Y, Nemoto K, Booka E, Matsubara H, Miyazaki T, Muto M, Yanagisawa A, Yoshida M. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus. 2019;16:1-24. [PMID: 30171413 DOI: 10.1007/s10388-018-0641-9] [Cited by in Crossref: 138] [Cited by in F6Publishing: 98] [Article Influence: 46.0] [Reference Citation Analysis]
373 Ratosa I, Oblak I, Anderluh F, Velenik V, But-Hadzic J, Ermenc AS, Jeromen A. Preoperative treatment with radiochemotherapy for locally advanced gastroesophageal junction cancer and unresectable locally advanced gastric cancer. Radiol Oncol. 2015;49:163-172. [PMID: 26029028 DOI: 10.2478/raon-2014-0027] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
374 Chen J, Hu B, Wang W, Qian XJ, Shan BJ, He YF. A six-microRNA signature to predict outcomes of patients with gastric cancer. FEBS Open Bio 2019;9:538-47. [PMID: 30868062 DOI: 10.1002/2211-5463.12593] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
375 Zou K, Yang S, Zheng L, Yang C, Xiong B. Efficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system review. BMC Cancer 2016;16:737. [PMID: 27633381 DOI: 10.1186/s12885-016-2772-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
376 Seshadri RA, Glehen O. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol 2016;22:1114-30. [PMID: 26811651 DOI: 10.3748/wjg.v22.i3.1114] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
377 Rocha-Filho DR, Peixoto RD, Weschenfelder RF, Rego JFM, Riechelmann R, Coutinho AK, Fernandes GS, Jacome AA, Andrade AC, Murad AM, Mello CAL, Miguel DSCG, Gomes DBD, Racy DJ, Moraes ED, Akaishi EH, Carvalho ES, Mello ES, Filho FM, Coimbra FJF, Capareli FC, Arruda FF, Vieira FMAC, Takeda FR, Cotti GCC, Pereira GLS, Paulo GA, Ribeiro HSC, Lourenco LG, Crosara M, Toneto MG, Oliveira MB, de Lourdes Oliveira M, Begnami MD, Forones NM, Yagi O, Ashton-Prolla P, Aguillar PB, Amaral PCG, Hoff PM, Araujo RLC, Di Paula Filho RP, Gansl RC, Gil RA, Pfiffer TEF, Souza T, Ribeiro U Jr, Jesus VHF, Costa WL Jr, Prolla G. Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of oesophageal cancer. Ecancermedicalscience 2021;15:1195. [PMID: 33889204 DOI: 10.3332/ecancer.2021.1195] [Reference Citation Analysis]
378 Wang Q, Liu X, Chen C, Chen J, Xu B, Chen L, Zhou J, Huang Y, Chen W, Teng R, Zhao W, Jin L, Shen J, Shen J, Yen Y, Wang L. A predictive signature for oxaliplatin and 5-fluorouracil based chemotherapy in locally advanced gastric cancer. Transl Oncol 2021;14:100901. [PMID: 33091827 DOI: 10.1016/j.tranon.2020.100901] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
379 Zhou ML, Kang M, Li GC, Guo XM, Zhang Z. Postoperative chemoradiotherapy versus chemotherapy for R0 resected gastric cancer with D2 lymph node dissection: an up-to-date meta-analysis. World J Surg Oncol 2016;14:209. [PMID: 27502921 DOI: 10.1186/s12957-016-0957-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
380 Mine S, Watanabe M, Imamura Y, Okamura A, Kurogochi T, Sano T. Clinical Significance of the Pre-therapeutic Nodal Size in Patients Undergoing Neo-Adjuvant Treatment Followed by Esophagectomy for Esophageal Squamous Cell Carcinoma. World J Surg 2017;41:184-90. [PMID: 27468743 DOI: 10.1007/s00268-016-3675-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
381 Cunningham D, Stenning SP, Smyth EC, Okines AF, Allum WH, Rowley S, Stevenson L, Grabsch HI, Alderson D, Crosby T, Griffin SM, Mansoor W, Coxon FY, Falk SJ, Darby S, Sumpter KA, Blazeby JM, Langley RE. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. Lancet Oncol 2017;18:357-70. [PMID: 28163000 DOI: 10.1016/S1470-2045(17)30043-8] [Cited by in Crossref: 137] [Cited by in F6Publishing: 56] [Article Influence: 34.3] [Reference Citation Analysis]
382 Lordick F, Ott K, Sendler A. [Gastric cancer and adenocarcinoma of the esophagogastric junction: principles of neoadjuvant therapy]. Chirurg 2011;82:968-73. [PMID: 22002702 DOI: 10.1007/s00104-011-2127-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
383 Bauer K, Porzsolt F, Henne-Bruns D. Can perioperative chemotherapy for advanced gastric cancer be recommended on the basis of current research? A critical analysis. J Gastric Cancer. 2014;14:39-46. [PMID: 24765536 DOI: 10.5230/jgc.2014.14.1.39] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
384 Yu Y, Fang Y, Shen Z, Wang Y, Yan M, Cao H, Liu Y, Wang X, Cui Y, Liu F, Chen W, Li W, Li Q, Jiang H, Sun Y, Liu T. Oxaliplatin plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy: NEO-CLASSIC Study. Oncologist. 2019;. [PMID: 31239311 DOI: 10.1634/theoncologist.2019-0416] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
385 Mukherjee S, Hurt C, Radhakrishna G, Gwynne S, Bateman A, Gollins S, Hawkins MA, Canham J, Grabsch HI, Falk S, Sharma RA, Ray R, Roy R, Cox C, Maynard N, Nixon L, Sebag-Montefiore DJ, Maughan T, Griffiths GO, Crosby TDL. Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial. Eur J Cancer 2021;153:153-61. [PMID: 34157617 DOI: 10.1016/j.ejca.2021.05.020] [Reference Citation Analysis]
386 Kim YW, Kim MJ, Ryu KW, Lim HS, Lee JH, Kong SY, Lee JS, Choi IJ, Kim CG, Lee JY, Cho SJ, Kook MC, Park YI, Kim SK, Park SR. A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival. Gastric Cancer 2016;19:586-96. [PMID: 25851942 DOI: 10.1007/s10120-015-0490-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
387 Giacopuzzi S, Bencivenga M, Weindelmayer J, Verlato G, de Manzoni G. Western strategy for EGJ carcinoma. Gastric Cancer. 2017;20:60-68. [PMID: 28039533 DOI: 10.1007/s10120-016-0685-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 5.6] [Reference Citation Analysis]
388 Müller B, García C, Sola JA, Fernandez W, Werner P, Cerda M, Slater J, Benavides C, Arancibia J, Ascui R, Reyes F, Stevens MA, Miranda JP, Buchholtz M, Corvalan AH. Perioperative chemotherapy in locally advanced gastric cancer in Chile: from evidence to daily practice. Ecancermedicalscience 2021;15:1244. [PMID: 34267800 DOI: 10.3332/ecancer.2021.1244] [Reference Citation Analysis]
389 Feng D, Leong M, Li T, Chen L. Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy. World J Surg Oncol. 2015;13:11. [PMID: 25634099 DOI: 10.1186/s12957-015-0444-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
390 Bose K, Franck C, Müller MN, Canbay A, Link A, Venerito M. Perioperative Therapy of Oesophagogastric Adenocarcinoma: Mainstay and Future Directions. Gastroenterol Res Pract 2017;2017:5651903. [PMID: 28785280 DOI: 10.1155/2017/5651903] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
391 Sharma R, Mapelli P, Hanna GB, Goldin R, Power D, Al-Nahhas A, Merchant S, Ramaswami R, Challapalli A, Barwick T, Aboagye EO. Evaluation of 18F-fluorothymidine positron emission tomography ([18F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer. EJNMMI Res 2016;6:81. [PMID: 27854031 DOI: 10.1186/s13550-016-0234-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
392 Schirren R, Novotny A, Oesterlin C, Slotta-Huspenina J, Friess H, Reim D. Significance of Lauren Classification in Patients Undergoing Neoadjuvant/Perioperative Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Cancers-Analysis from a Large Single Center Cohort in Germany. Cancers (Basel) 2021;13:290. [PMID: 33466779 DOI: 10.3390/cancers13020290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
393 Mulder KE, Ahmed S, Davies JD, Doll CM, Dowden S, Gill S, Gordon V, Hebbard P, Lim H, McFadden A, McGhie JP, Park J, Wong R. Report from the 17th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Edmonton, Alberta; 11-12 September 2015. Curr Oncol. 2016;23:425-434. [PMID: 28050139 DOI: 10.3747/co.23.3384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
394 Blank S, Rachakonda S, Keller G, Weichert W, Lordick F, Langer R, Springfeld C, Bruckner T, Becker K, Kumar R, Ott K. A retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients. BMC Cancer 2014;14:58. [PMID: 24490800 DOI: 10.1186/1471-2407-14-58] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
395 Kidane B, Coughlin S, Vogt K, Malthaner R. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev. 2015;CD001556. [PMID: 25988291 DOI: 10.1002/14651858.cd001556.pub3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
396 Altorki N, Harrison S. What is the role of neoadjuvant chemotherapy, radiation, and adjuvant treatment in resectable esophageal cancer? Ann Cardiothorac Surg. 2017;6:167-174. [PMID: 28447006 DOI: 10.21037/acs.2017.03.16] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
397 Koerfer J, Kallendrusch S, Merz F, Wittekind C, Kubick C, Kassahun WT, Schumacher G, Moebius C, Gaßler N, Schopow N, Geister D, Wiechmann V, Weimann A, Eckmann C, Aigner A, Bechmann I, Lordick F. Organotypic slice cultures of human gastric and esophagogastric junction cancer. Cancer Med 2016;5:1444-53. [PMID: 27073068 DOI: 10.1002/cam4.720] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
398 Sohda M, Kuwano H. Current Status and Future Prospects for Esophageal Cancer Treatment. Ann Thorac Cardiovasc Surg. 2017;23:1-11. [PMID: 28003586 DOI: 10.5761/atcs.ra.16-00162] [Cited by in Crossref: 83] [Cited by in F6Publishing: 70] [Article Influence: 16.6] [Reference Citation Analysis]
399 Soleyman-Jahi S, Abdirad A, Fallah AA, Ghasemi S, Sadeghi F, Heidari R, Mahmoodzadeh H, Zendehdel K. Prognostic Significance of Preoperative and Postoperative Plasma Levels of Ghrelin in Gastric Cancer: 3-Year Survival Study. Clin Transl Gastroenterol 2017;8:e209. [PMID: 28055030 DOI: 10.1038/ctg.2016.64] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
400 Ridwelski K, Gastinger I, Ptok H, Meyer F, Dralle H, Lippert H. [Surgical treatment of gastric carcinoma. German multicenter observational studies]. Chirurg. 2013;84:46-52. [PMID: 23329311 DOI: 10.1007/s00104-012-2394-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
401 Toneto MG, Viola L. CURRENT STATUS OF THE MULTIDISCIPLINARY TREATMENT OF GASTRIC ADENOCARCINOMA. Arq Bras Cir Dig 2018;31:e1373. [PMID: 29972401 DOI: 10.1590/0102-672020180001e1373] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
402 Ostwal V, Sahu A, Ramaswamy A, Sirohi B, Bose S, Talreja V, Goel M, Patkar S, Desouza A, Shrikhande SV. Perioperative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy in Locally Advanced Gastric Cancer: Safety and Feasibility in an Interim Survival Analysis. J Gastric Cancer 2017;17:21-32. [PMID: 28337360 DOI: 10.5230/jgc.2017.17.e3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
403 Schwarz RE. Current status of management of malignant disease: current management of gastric cancer. J Gastrointest Surg. 2015;19:782-788. [PMID: 25591828 DOI: 10.1007/s11605-014-2707-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
404 Kilic L, Ordu C, Yildiz I, Sen F, Keskin S, Ciftci R, Pilanci KN. Current adjuvant treatment modalities for gastric cancer: From history to the future. World J Gastrointest Oncol. 2016;8:439-449. [PMID: 27190583 DOI: 10.4251/wjgo.v8.i5.439] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
405 Svensson MC, Borg D, Zhang C, Hedner C, Nodin B, Uhlén M, Mardinoglu A, Leandersson K, Jirström K. Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival. Front Oncol 2019;9:136. [PMID: 30931254 DOI: 10.3389/fonc.2019.00136] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
406 Zhao J, Zhao J, Du F, Zhang Y, Shen G, Zhu H, Ji F, Ma F, Dong L, Kan J, Zheng F, Chen H, Wang Z, Xu B. Cardia and Non-Cardia Gastric Cancer Have Similar Stage-for-Stage Prognoses After R0 Resection: a Large-Scale, Multicenter Study in China. J Gastrointest Surg 2016;20:700-7. [PMID: 26831062 DOI: 10.1007/s11605-016-3089-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
407 Zhou J, Shen J, Seifer BJ, Jiang S, Wang J, Xiong H, Xie L, Wang L, Sui X. Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer. Oncotarget 2017;8:30477-94. [PMID: 27802185 DOI: 10.18632/oncotarget.12955] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
408 Li Y, Wei Y, He Q, Wang X, Fan C, Li G. Clinicopathological and prognostic significance of high circulating lymphocyte ratio in patients receiving neoadjuvant chemotherapy for advanced gastric cancer. Sci Rep 2018;8:6223. [PMID: 29670115 DOI: 10.1038/s41598-018-24259-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
409 Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach. J Gastric Cancer 2019;19:1-48. [PMID: 30944757 DOI: 10.5230/jgc.2019.19.e8] [Cited by in Crossref: 103] [Cited by in F6Publishing: 93] [Article Influence: 51.5] [Reference Citation Analysis]
410 Ashok A, Tiwari V, Jiwnani S, Karimundackal G, Pramesh CS. Controversies in preoperative therapy in esophageal cancer: Current evidence and ongoing research. Ann Gastroenterol Surg 2019;3:592-7. [PMID: 31788647 DOI: 10.1002/ags3.12301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
411 Wang X, Zhao L, Liu H, Zhong D, Liu W, Shan G, Dong F, Gao W, Bai C, Li X. A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer. Br J Cancer 2016;114:1326-33. [PMID: 27172250 DOI: 10.1038/bjc.2016.126] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
412 Nilsson PJ, van Etten B, Hospers GA, Påhlman L, van de Velde CJ, Beets-Tan RG, Blomqvist L, Beukema JC, Kapiteijn E, Marijnen CA, Nagtegaal ID, Wiggers T, Glimelius B. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer--the RAPIDO trial. BMC Cancer 2013;13:279. [PMID: 23742033 DOI: 10.1186/1471-2407-13-279] [Cited by in Crossref: 198] [Cited by in F6Publishing: 148] [Article Influence: 24.8] [Reference Citation Analysis]
413 Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, Ryu MH, Rha SY, Chung IJ, Kim IH, Oh SC, Park YS, Son T, Jung MR, Heo MH, Kim HK, Park C, Yoo CH, Choi JH, Zang DY, Jang YJ, Sul JY, Kim JG, Kim BS, Beom SH, Cho SH, Ryu SW, Kook MC, Ryoo BY, Kim HK, Yoo MW, Lee NS, Lee SH, Kim G, Lee Y, Lee JH, Noh SH. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin Oncol 2021;39:2903-13. [PMID: 34133211 DOI: 10.1200/JCO.20.02914] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
414 Li X, Huang Q, Lei Y, Zheng X, Dai S, Leng W, Liu M. Locally advanced gastroesophageal junction cancer with pathological complete response to neoadjuvant therapy: a case report and literature review. Ann Transl Med 2021;9:513. [PMID: 33850910 DOI: 10.21037/atm-21-434] [Reference Citation Analysis]
415 Mayanagi S, Irino T, Kawakubo H, Kitagawa Y. Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer. Ann Gastroenterol Surg 2019;3:269-75. [PMID: 31131355 DOI: 10.1002/ags3.12243] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
416 Rees J, Hurt CN, Gollins S, Mukherjee S, Maughan T, Falk SJ, Staffurth J, Ray R, Bashir N, Geh JI, Cunningham D, Roy R, Bridgewater J, Griffiths G, Nixon LS, Blazeby JM, Crosby T. Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer. Br J Cancer 2015;113:603-10. [PMID: 26203761 DOI: 10.1038/bjc.2015.258] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
417 Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8:CD004064. [PMID: 28850174 DOI: 10.1002/14651858.cd004064.pub4] [Cited by in Crossref: 77] [Cited by in F6Publishing: 147] [Article Influence: 19.3] [Reference Citation Analysis]
418 Wang Y, Zhang J, Guo S, Meng XY, Zheng ZC, Zhao Y. Indications of neoadjuvant chemotherapy for locally advanced Gastric Cancer patients based on pre-treatment clinicalpathological and laboratory parameters. J Cancer 2020;11:6000-8. [PMID: 32922540 DOI: 10.7150/jca.46430] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
419 Giampieri R, Del Prete M, Cantini L, Baleani MG, Bittoni A, Maccaroni E, Berardi R. Optimal management of resected gastric cancer. Cancer Manag Res 2018;10:1605-18. [PMID: 29950898 DOI: 10.2147/CMAR.S151552] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
420 Martin-Richard M, Díaz Beveridge R, Arrazubi V, Alsina M, Galan Guzmán M, Custodio AB, Gómez C, Muñoz FL, Pazo R, Rivera F. SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016). Clin Transl Oncol 2016;18:1179-86. [PMID: 27900538 DOI: 10.1007/s12094-016-1577-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
421 Wang FH, Shen L, Li J, Zhou ZW, Liang H, Zhang XT, Tang L, Xin Y, Jin J, Zhang YJ, Yuan XL, Liu TS, Li GX, Wu Q, Xu HM, Ji JF, Li YF, Wang X, Yu S, Liu H, Guan WL, Xu RH. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun (Lond). 2019;39:10. [PMID: 30885279 DOI: 10.1186/s40880-019-0349-9] [Cited by in Crossref: 123] [Cited by in F6Publishing: 98] [Article Influence: 61.5] [Reference Citation Analysis]
422 Liu Y, Cao Y, Xiao L, Wang H. Early myelostimulation in patients with locally advanced gastric cancer after fluorouracil plus platinum-based neoadjuvant chemotherapy is related to poor prognosis. Cancer Chemother Pharmacol 2021;87:701-10. [PMID: 33611625 DOI: 10.1007/s00280-021-04243-z] [Reference Citation Analysis]
423 Park H, Jin RU, Wang-Gillam A, Suresh R, Rigden C, Amin M, Tan BR, Pedersen KS, Lim KH, Trikalinos NA, Acharya A, Copsey ML, Navo KA, Morton AE, Gao F, Lockhart AC. FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol 2020;6:1231-40. [PMID: 32469386 DOI: 10.1001/jamaoncol.2020.2020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
424 Sun KY, Hu HT, Chen SL, Ye JN, Li GH, Chen LD, Peng JJ, Feng ST, Yuan YJ, Hou X, Wu H, Li X, Wu TF, Wang W, Xu JB. CT-based radiomics scores predict response to neoadjuvant chemotherapy and survival in patients with gastric cancer. BMC Cancer 2020;20:468. [PMID: 32450841 DOI: 10.1186/s12885-020-06970-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
425 Smyth EC, Fassan M, Cunningham D, Allum WH, Okines AF, Lampis A, Hahne JC, Rugge M, Peckitt C, Nankivell M, Langley R, Ghidini M, Braconi C, Wotherspoon A, Grabsch HI, Valeri N. Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. J Clin Oncol. 2016;34:2721-2727. [PMID: 27298411 DOI: 10.1200/jco.2015.65.7692] [Cited by in Crossref: 115] [Cited by in F6Publishing: 56] [Article Influence: 23.0] [Reference Citation Analysis]
426 Eom BW, Kim S, Kim JY, Yoon HM, Kim MJ, Nam BH, Kim YW, Park YI, Park SR, Ryu KW. Survival Benefit of Perioperative Chemotherapy in Patients with Locally Advanced Gastric Cancer: a Propensity Score Matched Analysis. J Gastric Cancer. 2018;18:69-81. [PMID: 29629222 DOI: 10.5230/jgc.2018.18.e9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
427 Dinneen K, Baird AM, Ryan C, Sheils O. The Role of Cancer Stem Cells in Drug Resistance in Gastroesophageal Junction Adenocarcinoma. Front Mol Biosci 2021;8:600373. [PMID: 33628765 DOI: 10.3389/fmolb.2021.600373] [Reference Citation Analysis]
428 He J, Shi H, Zhou Z, Chen J, Guan W, Wang H, Yu H, Liu S, Zhou Z, Yang X, Liu T. Correlation between apparent diffusion coefficients and HER2 status in gastric cancers: pilot study. BMC Cancer 2015;15:749. [PMID: 26487555 DOI: 10.1186/s12885-015-1726-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
429 Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10:643-655. [PMID: 24061039 DOI: 10.1038/nrclinonc] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
430 Sisic L, Blank S, Weichert W, Jäger D, Springfeld C, Hochreiter M, Büchler M, Ott K. Prognostic impact of lymph node involvement and the extent of lymphadenectomy (LAD) in adenocarcinoma of the esophagogastric junction (AEG). Langenbecks Arch Surg 2013;398:973-81. [PMID: 23887283 DOI: 10.1007/s00423-013-1101-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
431 Stewart C, Chao J, Chen YJ, Lin J, Sullivan MJ, Melstrom L, Hyung WJ, Fong Y, Paz IB, Woo Y. Multimodality management of locally advanced gastric cancer-the timing and extent of surgery. Transl Gastroenterol Hepatol 2019;4:42. [PMID: 31231709 DOI: 10.21037/tgh.2019.05.02] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
432 Koldby KM, Mortensen MB, Detlefsen S, Pfeiffer P, Thomassen M, Kruse TA. Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients. J Gastroenterol 2019;54:108-21. [PMID: 30242476 DOI: 10.1007/s00535-018-1508-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
433 Quéro L, Guillerm S, Hennequin C. Neoadjuvant or adjuvant therapy for gastric cancer. World J Gastrointest Oncol 2015;7:102-10. [PMID: 26306142 DOI: 10.4251/wjgo.v7.i8.102] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
434 Gabriel E, Attwood K, Shah R, Nurkin S, Hochwald S, Kukar M. Novel Calculator to Estimate Overall Survival Benefit from Neoadjuvant Chemoradiation in Patients with Esophageal Adenocarcinoma. J Am Coll Surg 2017;224:884-894.e1. [PMID: 28147252 DOI: 10.1016/j.jamcollsurg.2017.01.043] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
435 De Vita F, Di Martino N, Fabozzi A, Laterza MM, Ventriglia J, Savastano B, Petrillo A, Gambardella V, Sforza V, Marano L, Auricchio A, Galizia G, Ciardiello F, Orditura M. Clinical management of advanced gastric cancer: the role of new molecular drugs. World J Gastroenterol 2014;20:14537-58. [PMID: 25356019 DOI: 10.3748/wjg.v20.i40.14537] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
436 Watanabe M, Otake R, Kozuki R, Toihata T, Takahashi K, Okamura A, Imamura Y. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today 2020;50:12-20. [PMID: 31535225 DOI: 10.1007/s00595-019-01878-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 20.0] [Reference Citation Analysis]
437 Achilli P, De Martini P, Ceresoli M, Mari GM, Costanzi A, Maggioni D, Pugliese R, Ferrari G. Tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma: a prospective, multi-center cohort study. J Gastrointest Oncol. 2017;8:1018-1025. [PMID: 29299362 DOI: 10.21037/jgo.2017.08.13] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
438 Allen CJ, Blumenthaler AN, Smith GL, Das P, Minsky BD, Blum M, Ajani J, Mansfield PF, Ikoma N, Badgwell BD. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Preoperative Therapy for Resectable Gastric Adenocarcinoma: A Propensity Score-Matched Analysis of a Large, Single-Institution Experience. Ann Surg Oncol 2021;28:758-65. [PMID: 32696305 DOI: 10.1245/s10434-020-08864-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
439 Cho I, Kwon IG, Guner A, Son T, Kim HI, Kang DR, Noh SH, Lim JS, Hyung WJ. Consideration of clinicopathologic features improves patient stratification for multimodal treatment of gastric cancer.Oncotarget. 2017;8:79594-79603. [PMID: 29108339 DOI: 10.18632/oncotarget.18607] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
440 Bouriez D, Giraud J, Gronnier C, Varon C. Efficiency of All-Trans Retinoic Acid on Gastric Cancer: A Narrative Literature Review. Int J Mol Sci 2018;19:E3388. [PMID: 30380687 DOI: 10.3390/ijms19113388] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
441 Martín-Richard M, Carmona-Bayonas A, Custodio AB, Gallego J, Jiménez-Fonseca P, Reina JJ, Richart P, Rivera F, Alsina M, Sastre J. SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019). Clin Transl Oncol 2020;22:236-44. [PMID: 31989475 DOI: 10.1007/s12094-019-02259-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
442 Fu Q, Wang J, Liu H. Chemo-immune synergetic therapy of esophageal carcinoma: trastuzumab modified, cisplatin and fluorouracil co-delivered lipid-polymer hybrid nanoparticles. Drug Deliv 2020;27:1535-43. [PMID: 33118428 DOI: 10.1080/10717544.2020.1837294] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
443 Glatz T, Höppner J. Is There a Rationale for Structural Quality Assurance in Esophageal Surgery? Visc Med 2017;33:135-9. [PMID: 28560229 DOI: 10.1159/000458454] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
444 Cartwright E, Cunningham D. The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer. Curr Treat Options Oncol 2017;18:69. [PMID: 29143893 DOI: 10.1007/s11864-017-0510-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
445 Monti M, Morgagni P, Nanni O, Framarini M, Saragoni L, Marrelli D, Roviello F, Petrioli R, Fumagalli Romario U, Rimassa L, Bozzarelli S, Donini A, Graziosi L, De Angelis V, De Manzoni G, Bencivenga M, Mengardo V, Parma E, Milandri C, Mura G, Signorini A, Baiocchi G, Molfino S, Sgroi G, Steccanella F, Rausei S, Proserpio I, Viganò J, Brugnatelli S, Rinnovati A, Santi S, Ercolani G, Foca F, Valmorri L, Amadori D, Frassineti GL. Preoperative or Perioperative Docetaxel, Oxaliplatin, and Capecitabine (GASTRODOC Regimen) in Patients with Locally-Advanced Resectable Gastric Cancer: A Randomized Phase-II Trial. Cancers (Basel) 2020;12:E2790. [PMID: 33003302 DOI: 10.3390/cancers12102790] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
446 Li Z, Li S, Ying X, Zhang L, Shan F, Jia Y, Ji J. The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy. Gastric Cancer 2020;23:540-9. [PMID: 32072387 DOI: 10.1007/s10120-019-01027-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
447 Nie RC, Yuan SQ, Chen XJ, Chen S, Xu LP, Chen YM, Zhu BY, Sun XW, Zhou ZW, Chen YB. Endoscopic ultrasonography compared with multidetector computed tomography for the preoperative staging of gastric cancer: a meta-analysis. World J Surg Oncol 2017;15:113. [PMID: 28577563 DOI: 10.1186/s12957-017-1176-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
448 Kim C, Mulder K, Spratlin J. How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer. Oncologist. 2014;19:1046-1055. [PMID: 25142842 DOI: 10.1634/theoncologist.2014-0006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
449 Iams WT, Villaflor VM. Neoadjuvant Treatment for Locally Invasive Esophageal Cancer. World J Surg 2017;41:1719-25. [PMID: 28271259 DOI: 10.1007/s00268-017-3959-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
450 Lin JX, Xu YC, Lin W, Xue FQ, Ye JX, Zang WD, Cai LS, You J, Xu JH, Cai JC, Tang YH, Xie JW, Li P, Zheng CH, Huang CM. Effectiveness and Safety of Apatinib Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer: A Nonrandomized Controlled Trial. JAMA Netw Open 2021;4:e2116240. [PMID: 34241629 DOI: 10.1001/jamanetworkopen.2021.16240] [Reference Citation Analysis]
451 Wei Z, Tan B, Cao S, Liu S, Tan X, Yao Z, Yin N, Li J, Zhang D, Zhou Y. The influence of neoadjuvant chemotherapy on gastric cancer patients' postoperative infectious complications: What is the negative role played by the intestinal barrier dysfunction? Oncotarget 2017;8:43376-88. [PMID: 28118611 DOI: 10.18632/oncotarget.14758] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
452 Zhao X, Ren Y, Hu Y, Cui N, Wang X, Cui Y. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials. PLoS One 2018;13:e0202185. [PMID: 30138325 DOI: 10.1371/journal.pone.0202185] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
453 Openshaw MR, Mohamed AA, Ottolini B, Fernandez-Garcia D, Richards CJ, Page K, Guttery DS, Thomas AL, Shaw JA. Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma. Br J Cancer 2020;123:1271-9. [PMID: 32719550 DOI: 10.1038/s41416-020-1002-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
454 Mingol F, Gallego J, Orduña A, Martinez-Blasco A, Sola-Vera J, Moya P, Morcillo MA, Ruiz JA, Calpena R, Lacueva FJ. Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction. BMC Surg 2015;15:66. [PMID: 25997454 DOI: 10.1186/s12893-015-0054-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
455 Wang N, Zhou A, Jin J, Huang H, Zhang Y, Chen Y, Zhao D. Open vs. laparoscopic surgery for locally advanced gastric cancer after neoadjuvant therapy: Short-term and long-term survival outcomes. Oncol Lett 2020;20:861-7. [PMID: 32566013 DOI: 10.3892/ol.2020.11626] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
456 Yan H, Chen Y, Yang Z, Li Z, Che X, Xiao J, Liu Y, Qu X. An Immune Cell Signature Is Associated With Disease-Free Survival and Adjuvant Chemosensitivity of Patients With Resectable Gastric Cancer. Front Immunol 2020;11:621623. [PMID: 33613554 DOI: 10.3389/fimmu.2020.621623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
457 Chang AY, Foo KF, Koo WH, Ong S, So J, Tan D, Lim KH. Phase II study of neo-adjuvant chemotherapy for locally advanced gastric cancer. BMJ Open Gastroenterol 2016;3:e000095. [PMID: 27648294 DOI: 10.1136/bmjgast-2016-000095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
458 Seidlitz T, Koo BK, Stange DE. Gastric organoids-an in vitro model system for the study of gastric development and road to personalized medicine. Cell Death Differ 2021;28:68-83. [PMID: 33223522 DOI: 10.1038/s41418-020-00662-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
459 Badgwell B, Das P, Ajani J. Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of accurate staging and preoperative therapy. J Hematol Oncol 2017;10:149. [PMID: 28810883 DOI: 10.1186/s13045-017-0517-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
460 Chen W, Shen J, Pan T, Hu W, Jiang Z, Yuan X, Wang L. FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer. Exp Ther Med 2014;7:461-7. [PMID: 24396426 DOI: 10.3892/etm.2013.1449] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
461 Ikoma N, Das P, Hofstetter W, Ajani JA, Estrella JS, Chen HC, Wang X, Callender RA, Zhu C, Roland CL, Fournier KF, Cormier JN, Mansfield P, Badgwell BD. Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006-2014 using propensity score matching. Gastric Cancer 2018;21:1004-13. [PMID: 29730720 DOI: 10.1007/s10120-018-0832-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
462 Wang D, Li W, Yin L, Du Y, Zhang S, Suo J. Association of serum levels of deoxyribose 1-phosphate and S-lactoylglutathione with neoadjuvant chemotherapy sensitivity in patients with gastric cancer: A metabolomics study. Oncol Lett. 2020;19:2231-2242. [PMID: 32194721 DOI: 10.3892/ol.2020.11350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
463 Zhu R, Liu F, Grisotti G, Perez-Irizarry J, Salem RR, Cha CH, Johung KL, Boffa DJ, Zhang Y, Khan SA. Clinical impact of underutilization of adjuvant therapy in node positive gastric adenocarcinoma. J Gastrointest Oncol 2018;9:517-26. [PMID: 29998017 DOI: 10.21037/jgo.2018.03.05] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
464 Zhang N, Fei Q, Gu J, Yin L, He X. Progress of preoperative and postoperative radiotherapy in gastric cancer. World J Surg Oncol 2018;16:187. [PMID: 30213266 DOI: 10.1186/s12957-018-1490-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
465 Sasaki K, Onodera S, Otsuka K, Satomura H, Kurayama E, Kubo T, Takahashi M, Ito J, Nakajima M, Yamaguchi S, Miyachi K, Kato H. Validity of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 for resectable locally advanced gastric cancer. Med Oncol 2017;34:139. [PMID: 28707042 DOI: 10.1007/s12032-017-0997-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
466 Li B, Wang L, Li Z, Wang W, Zhi X, Huang X, Zhang Q, Chen Z, Zhang X, He Z, Xu J, Zhang L, Xu H, Zhang D, Xu Z. miR-3174 Contributes to Apoptosis and Autophagic Cell Death Defects in Gastric Cancer Cells by Targeting ARHGAP10. Mol Ther Nucleic Acids 2017;9:294-311. [PMID: 29246308 DOI: 10.1016/j.omtn.2017.10.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
467 Gotfrit J, Goodwin R, Asmis T, Hyde AJ, Alcindor T, Aubin F, Berry S, Bossé D, Brown C, Burkes R, Burnell M, Colwell B, Corbett J, Craswell J, Daaboul N, Doherty M, Fleming DAB, Galvis L, Goel R, Harb M, Jeyakumar A, Jonker D, Kennedy E, Lock M, Mahmud A, McCrea PH, Nair V, Nassabein R, Nessim C, Ramjeesingh R, Raza M, Saliba W, Samimi S, Singh S, Snow S, Tehfé M, Thirlwell M, Valdes M, Welch S, Vickers M. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019. Curr Oncol 2021;28:1988-2006. [PMID: 34073199 DOI: 10.3390/curroncol28030185] [Reference Citation Analysis]
468 Sehdev A, Catenacci DV. Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care. J Hematol Oncol 2013;6:66. [PMID: 24010946 DOI: 10.1186/1756-8722-6-66] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
469 Villaflor VM, Allaix ME, Minsky B, Herbella FA, Patti MG. Multidisciplinary approach for patients with esophageal cancer. World J Gastroenterol 2012;18:6737-46. [PMID: 23239911 DOI: 10.3748/wjg.v18.i46.6737] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
470 Tong Z, Mejia A, Veeranki O, Verma A, Correa AM, Dokey R, Patel V, Solis LM, Mino B, Kathkuda R, Rodriguez-Canales J, Lin SH, Krishnan S, Kopetz S, Blum M, Ajani JA, Hofstetter WL, Maru DM. Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma. Ther Adv Med Oncol 2019;11:1758835919864850. [PMID: 31384313 DOI: 10.1177/1758835919864850] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
471 Newton AD, Datta J, Loaiza-Bonilla A, Karakousis GC, Roses RE. Neoadjuvant therapy for gastric cancer: current evidence and future directions. J Gastrointest Oncol. 2015;6:534-543. [PMID: 26487948 DOI: 10.3978/j.issn.2078-6891.2015.047] [Cited by in F6Publishing: 26] [Reference Citation Analysis]